

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> A61K 35/12, 38/00, 38/21, 39/00, 39/385, 45/00, 45/05, 47/00, A01N 37/18, C12P 19/34, C12Q 1/68, G01N 33/531	<b>A1</b>	<b>(11) International Publication Number:</b> WO 96/40173  <b>(43) International Publication Date:</b> 19 December 1996 (19.12.96)
<b>(21) International Application Number:</b> PCT/US96/09511  <b>(22) International Filing Date:</b> 6 June 1996 (06.06.96)  <b>(30) Priority Data:</b> 08/479,016 7 June 1995 (07.06.95) US  <b>(60) Parent Application or Grant</b> <b>(63) Related by Continuation</b> US 08/479,016 (CON) Filed on 7 June 1995 (07.06.95)  <b>(71) Applicant (for all designated States except US):</b> THOMAS JEFFERSON UNIVERSITY [US/US]; 11th and Walnut Streets, Philadelphia, PA 19107 (US).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> BERD, David [US/US]; 125 Heathcock Lane, Wyncote, PA 19095 (US). EISEN- LOHR, Lawrence, C. [US/US]; 110 Rockland Avenue, Merion Station, PA 19066 (US). LATTIME, Edmund [US/US]; 600 Sayre Drive, Princeton, NJ 08540 (US).	<b>(74) Agents:</b> JOHNSON, Philip, S. et al.; Woodcock Washburn Kurtz Mackiewicz & Norris, 46th floor, One Liberty Place, Philadelphia, PA 19103 (US).  <b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>With amended claims and statement.</i>	
<b>(54) Title:</b> HAPTEN MODIFIED TUMOR CELL EXTRACT AND METHODS OF TREATING OR SCREENING FOR CANCER		
<b>(57) Abstract</b>  A novel composition comprising a hapten modified tumor cell extract prepared from cancer cells, or cancer cell membranes or peptides obtained therefrom is disclosed. Also disclosed are methods of treating cancer comprising administering therapeutically effective amounts of cyclophosphamide and hapten modified tumor cell extracts, with or without adjuvants and cytokines. Also disclosed is a method of screening for cytokine production by tumors in order to determine the efficacy of treatment, wherein cytokin-specific nucleic acids from a patient tissue sample are amplified in order to produce a detectable signal.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

**"HAPTEN  
MODIFIED TUMOR CELL EXTRACT AND METHODS OF TREATING OR SCREENING  
FOR CANCER"**

**REFERENCE TO RELATED APPLICATIONS**

This application is a continuation-in-part of  
5 application Serial No. 08/203,004, filed February 28, 1994,  
which is a continuation-in-part of application Serial No.  
07/985,334, filed December 4, 1992, now U.S. Patent  
5,290,551, which is a continuation of application Serial No.  
07/520,649, filed May 8, 1990, now abandoned.

10

**REFERENCE TO GOVERNMENT GRANTS**

The invention described herein was made in the  
course of work under a grant or award from an NIH Cancer  
Research grant, grant no. CA39248. The United States  
15 Government may have certain rights in this invention. Some  
of this invention was disclosed in a Disclosure Document  
filed with the U.S. Patent and Trademark Office on April 18,  
1990.

- 2 -

**BACKGROUND OF THE INVENTION**

It was theorized in the 1960's that tumor cells bear specific antigens (TSA) which are not present on normal cells and that the immune response to these antigens might enable an individual to reject a tumor. It was later suggested that the immune response to TSA could be increased by introducing new immunological determinants on cells. Mitchison, *Transplant. Proc.*, 1970, 2, 92. Such a "helper determinant", which can be a hapten, a protein, a viral coat antigen, a transplantation antigen, or a xenogenous cell antigen, could be introduced into a population of tumor cells. The cells would then be injected into an individual who would be expected to be tolerant to the growth of unmodified tumor cells. Clinically, the hope was that an immunologic reaction would occur against the helper determinants, as a consequence of which the reaction to the accompanying TSA is increased, and tumor cells which would otherwise be tolerated are destroyed. Mitchison, *supra*, also suggests several modes of action of the helper determinants including 1) that the unmodified cells are merely attenuated, in the sense that their growth rate is slowed down or their susceptibility to immunologic attack increased; 2) that helper determinants merely provide points of attack and so enable the modified cells to be killed by an immune response not directed against TSA; 3) that the helper determinants have an adjuvant action such as binding to an antibody or promoting localization of the cells in the



- 3 -

right part of the body for immunization, in particular, in lymph nodes.

Fujiwara et al., *J. Immunol.*, 1984a, 132, 1571 showed that tumor cells conjugated with the hapten, trinitrophenyl (TNP), could induce systemic immunity against unmodified tumor cells in a murine system, provided that the mice were first sensitized to the hapten in the absence of hapten-specific suppressor T cells. Spleen cells from the treated mice completely and specifically prevented the growth of tumors in untreated recipient animals. Flood et al., *J. Immunol.*, 1987, 138, 3573 showed that mice immunized with a TNP-conjugated, ultraviolet light-induced "regressor" tumor were able to reject a TNP-conjugated "progressor" tumor that was otherwise non-immunologic. Moreover, these mice were subsequently resistant to challenge with unconjugated "progressor" tumor. In another experimental system, Fujiwara et al., *J. Immunol.*, 1984b, 133, 510 demonstrated that mice sensitized to trinitrochlorobenzene (TNCB) after cyclophosphamide pretreatment could be cured of large (10mm) tumors by *in situ* haptenization of tumor cells; subsequently, these animals were specifically resistant to challenge with unconjugated tumor cells.

The existence of T cells which cross-react with unmodified tissues has recently been demonstrated. Weltzien and coworkers have shown that class I MHC-restricted T cell clones generated from mice immunized with TNP-modified syngeneic lymphocytes respond to MHC-associated, TNP-modified "self" peptides. Ortmann, B., et al., *J. Immunol.*,

- 4 -

1992, 148, 1445. In addition, it has been established that immunization of mice with TNP-modified lymphocytes results in the development of splenic T cells that exhibit secondary proliferative and cytotoxic responses to TNP-modified cells *in vitro*. Shearer, G. M. *Eur. J. Immunol.*, 1974, 4, 527. The potential of lymphocytes elicited by immunization with DNP- or TNP-modified autologous cells to respond to unmodified autologous cells is of considerable interest because it may be relevant to two clinical problems: 1) drug-induced autoimmune disease, and 2) cancer immunotherapy. In regard to the former, it has been suggested that ingested drugs act as haptens, which combine with normal tissue protein forming immunogenic complexes that are recognized by T cells. Tsutsui, H., et al., *J. Immunol.*, 1992, 149, 706. Subsequently, autoimmune disease, e.g., systemic lupus erythematosus, can develop and continue even after withdrawal of absence of the offending drug. This would imply the eventual generation of T lymphocytes that cross-react with unmodified tissues.

Others have shown that membranes or peptides from cells, and in one case a peptide from a virus, may elicit a T cell lymphocyte response *in vitro*. Heike, M., et al., *J. Immunotherapy*, 1994 15:165-174, disclose a method of stimulating mouse and human antitumor cytotoxic T lymphocytes (CTL) with plasma membrane preparations. This reference identifies differences among the reports of CTL responses and associates these differences with differences

- 5 -

in immunogenicity of the tumors used and the mode of immunization, for example.

Others report that the recognition of human melanoma cells by cytotoxic T cells is mediated by a number of peptides, Slingluff, C., et al., *J Immunology* 1993 150:2955-2963; Wolfel, T., et al., *Int. J. Cancer* 1994 57:413-418; and Castelli, C., et al., *J. Exp. Med.* 1995 181:363-368, the disclosures of each are incorporated herein by reference in its entirety. Each of these references indicates that there are a number of T cell defined epitopes which are unique to a given tumor. None of these references disclose a tumor cell extract which is obtained by hapten modification of a tumor cell.

The common denominator of these experiments is sensitization with hapten in a milieu in which suppressor cells are not induced. Spleen cells from cyclophosphamide pretreated, TNCB-sensitized mice exhibited radioresistant "amplified helper function" i.e., they specifically augmented the in vitro generation of anti-TNP cytotoxicity. Moreover, once these amplified helpers had been activated by in vitro exposure to TNP-conjugated autologous lymphocytes, they were able to augment cytotoxicity to unrelated antigens as well, including tumor antigens (Fujiwara et al., 1984b). Flood et al., (1987), *supra*, showed that this amplified helper activity was mediated by T cells with the phenotype Lyt<sup>1+</sup>, Lyt<sup>2-</sup>, L3T4<sup>+</sup>, I-J<sup>+</sup> and suggests that these cells were contrasuppressor cells, a new class of immunoregulatory T cell.

- 6 -

Immunotherapy of patients with melanoma has shown that administration of cyclophosphamide, at high dose (1000 mg/M<sup>2</sup>) or low dose (300 mg/M<sup>2</sup>), three days before sensitization with the primary antigen keyhole limpet hemocyanin markedly augments the acquisition of delayed type hypersensitivity to that antigen (Berd et al., *Cancer Res.*, 1982, 42, 4862; *Cancer Res.*, 1984a, 44, 1275). Low dose cyclophosphamide pretreatment allows patients with metastatic melanoma to develop delayed type hypersensitivity to autologous melanoma cells in response to injection with autologous melanoma vaccine (Berd et al., *Cancer Res.*, 1986, 46, 2572). The combination of low dose cyclophosphamide and vaccine can produce clinically important regression of metastatic tumor (Berd et al. (1986), *supra*; *Cancer Invest.*, 1988a, 6, 335). Cyclophosphamide administration results in reduction of peripheral blood lymphocyte non-specific T suppressor function (Berd et al., *Cancer Res.*, 1984b, 44, 5439; *Cancer Res.*, 1987, 47, 3317), possibly by depleting CD4+, CD45RA+ suppressor inducer T cells (Berd et al., *Cancer Res.*, 1988b, 48, 1671). The anti-tumor effects of this immunotherapy regimen appear to be limited by the excessively long interval between the initiation of vaccine administration and the development of delayed type hypersensitivity to the tumor cells (Berd et al., *Proc. Amer. Assoc. Cancer Res.*, 1988c, 29, 408 (#1626)).

Therefore, there remains a need to increase the therapeutic efficiency of such a vaccine to make it more immunogenic.

- 7 -

Most tumor immunologists now agree that T lymphocyte, white cells responsible for tumor immunity, infiltration into the tumor mass is a prerequisite for tumor destruction by the immune system. Consequently, a good deal of attention has been focused on what has become known as "TIL" therapy, as pioneered by Dr. Stephen Rosenberg at NCI. Dr. Rosenberg and others have extracted from human cancer metastases the few T lymphocytes that are naturally present and greatly expanded their numbers by culturing them in vitro with Interleukin 2 (IL2), a growth factor for T lymphocytes. Topalian et al., *J. Clin. Oncol.*, 1988, 6, 839. However this therapy has not been very effective because the injected T cells are limited in their ability to "home" to the tumor cite.

The ability of high concentrations of IL2 to induce lymphocytes to become non-specifically cytotoxic killer cells has been exploited therapeutically in a number of studies (Lotze et al., *J. Biol. Response*, 1982, 3, 475; West et al., *New Engl. J. Med.*, 1987, 316, 898). However, this approach has been limited by the severe toxicity of high dose intravenous IL2. Less attention has been given to the observation that much lower concentrations of IL2 can act as an immunological adjuvant by inducing the expansion of antigen activated T cells (Talmadge et al., *Cancer Res.*, 1987, 47, 5725; Meuer et al., *Lancet*, 1989, 1, 15).

Therefore, there remains a need to understand and attempt to exploit the use of IL2 as an immunological adjuvant.

- 8 -

Human melanomas are believed to express unique surface antigens recognizable by T lymphocytes. Old, L. J., *Cancer Res.*, 1981, 41, 361; Van der Bruggen, P., et al., *Science*, 1991, 254, 1643; Mukherji, B., et al., *J. Immunol.*, 5 1986, 136, 1888; and Anichini, A., et al., *J. Immunol.*, 1989, 142, 3692. However, immunotherapeutic approaches to date have been limited by the difficulty of inducing an effective T cell-mediated response to such antigens *in vivo*.

There are several models proposed to explicate 10 what appears to be tolerance to human tumor-associated antigens. They include:

1) Tumor antigen-specific suppressor cells that down-regulated incipient anti-tumor responses. Mukherji, et al., *supra*; Berendt, M. J. and R. J. North., *J. Exp. Med.*, 15 1980, 151, 69.

2) Failure of human tumor cells to elicit T helper cells or to provide costimulatory signals to those T cells. Fearon, E. R., et al., *Cell*, 1990, 60, 397; Townsend, S. E. and J. P. Allison, *Science*, 1993, 259, 368; and

20 3) Reduced surface expression of major histocompatibility products on tumor cells which limits their recognition by T cells. Ruiter, D. J., *Seminars in Cancer Biology*, 1991, 2, 35. None of these hypotheses has yet been corroborated in a clinical system.

25 The goal of active immunotherapy for tumors is the development of a productive systemic T cell mediated tumor-specific immunity. Tumor specific immunity would act both at the primary tumor site as well as in clearing small

- 9 -

metastatic foci at distant sites. The generation of T cell immunity has been shown to be a highly regulated response requiring cell-cell interaction and the production of a number of cytokines. Of late, studies in a number of human and murine systems have shown that T cell responses can be separated into two categories termed Type I and II (Mossmann, et al., *J. Immunol.* 1986 136:2348). Type I responses are required for the development of delayed type hypersensitivity (DTH), are associated with macrophage activation and the production of interferon-gamma (IFN $\gamma$ ), and have been shown to be associated with the resolution of human leprosy (Yamamura, M., et al., *Science* 1991 254:277-279) and murine leishmaniasis (Scott, P., et al., *Immunological Review* 1989 112:161-182). Type II responses are associated with the production of IL4 and IL10, primarily support antibody responses, and are associated with the progressive forms of leprosy (Yamamura, M., et al., *supra*) and leishmaniasis (Yamamura et al., *supra*; and Scott, P., et al., *supra*). In addition to the development of DTH, Type I responses would be expected to enhance the generation of tumor specific CTL via upregulation of MHC and tumor associated antigens as well as enhanced antigen presentation secondary to localized IFN $\gamma$  production. More recently, Type I and II responses have been shown to be cross regulating: IFN $\gamma$  inhibits Type II responses, while IL4 and IL10 inhibit Type I (Scott, *J. Immunol.* 1991 147:3149-3155; and Fiorentino et al., *J. Immunol.* 1991 146:3444-3451). In the leishmania system, modulation of cytokines at the lesion

- 10 -

site allows for the conversion of a Type II to a Type I response, and, consequently, a change from progressive infection to eradication of the disease (Scott, 1991, *supra*).

5                   Pisa et al., *Proc. Natl. Acad. Sci. USA* 1992  
89:7708-7712 detected IL10 mRNA in ovarian carcinoma biopsies, but not in ovarian carcinoma cell lines; they concluded that the source of IL10 was tumor-infiltrating lymphocytes. Gastl et al, *Int. J. Cancer* 1991 55:96-101  
10 found that 16/48 tumor cell lines released IL10 into the culture supernatant; only 3/8 melanoma cell lines were positive. Finally, Chen et al., *Int. J. Cancer*, 1994 56:755-760 recently reported that 6/9 cell lines derived from metastatic melanomas expressed IL10 mRNA. However, the  
15 present invention is the first report known to the inventors of mRNA for IL10 in metastatic melanoma biopsies.

It is not known whether these observations are applicable to the human tumor-host relationship, i.e., whether the pattern of cytokine production by T cells  
20 infiltrating tumors is an indicator of the effectiveness of the immune response. Patients with metastatic melanoma treated with an autologous, DNP-modified vaccine develop inflammatory responses at tumor sites, Berd et al., 1991, *supra*. Histologically, these inflamed lesions are  
25 characterized by T cell infiltration which is sometimes associated with tumor cell destruction. The present invention finds that tumors from DNP-vaccine-treated patients contain Type I T lymphocytes, which are not



- 11 -

detectable in tumors excised prior to vaccine administration.

#### SUMMARY OF THE INVENTION

The present invention is directed to a treatment  
5 for cancer. Compositions and methods of treating cancer are included in the scope of the present invention. The compositions of the present invention include a composition prepared from a tumor cell or tumor cell extract. The methods of the present invention are directed to treating  
10 cancer comprising administering a therapeutically effective amount of a composition comprising a tumor cell or tumor cell extract.

#### BRIEF DESCRIPTION OF THE FIGURES

Figure 1 displays the kinetics of the development  
15 of DTH to DNP-modified autologous PBL and melanoma cells. Patients with metastatic melanoma treated with DNP-vaccine were serially skin tested with DNP-modified PBL (LY) or DNP-modified melanoma cells dissociated from a metastatic mass (MEL). Each bar indicates the mean DTH response for the  
20 group of patients at each time point; error bars = standard error. For day 119, only responses to PBL were measured. Sample sizes: days 0, 14, 63 N = 84; day 119, N = 57; day 175, N = 42; day 231, N = 35.

Figure 2 exhibits antibody response to DNP. Serum  
25 obtained at various time points was tested for antibody (total immunoglobulin) to DNP using an ELISA. The titer was

- 12 -

defined as: (peak OD of sample) X (reciprocal of the dilution that gave an OD equal to half the peak OD of positive control).

Figure 3 is a graph of proliferative response of  
5 PBL to DNP-modified autologous lymphocytes. PBL were obtained from four patients receiving DNP-vaccine at the peak of their DTH responses. The cells were tested for ability to proliferate to DNP modified autologous PBL (autol LY-DNP) with unmodified autologous PBL (autol LY) as a  
10 control. Cultures were pulsed with  $^{125}$ IUDR on day 6.

Figure 4 shows the kinetics of the proliferative response to DNP-modified lymphocytes. PBL were serially collected from patient DM2 while receiving DNP vaccine. They were cryopreserved and then all samples were tested  
15 simultaneously for proliferative response to DNP-modified autologous PBL (autol LY-DNP). Cultures were pulsed with  $^{125}$ IUDR on day 6.

Figure 5 displays specificity of the proliferative response to DNP-modified cells. PBL from two patients were  
20 tested for proliferative response to autologous PBL, either unmodified (autol LY), DNP-modified (autol LY-DNP), or TNP-modified (autol LY-TNP), and to cultured autologous melanoma cells, either unmodified (MEL) or DNP-modified (MEL-DNP). Cultures were pulsed with  $^{125}$ IUDR on day 6.

25 Figure 6 is a specificity analysis of expanded T cells. PBL from patient DM2 were expanded in IL2 and repeatedly stimulated with autologous DNP-modified B lymphoblastoid cells. They were tested for proliferative

- 13 -

response to autologous PBL, either unmodified (autol LY), DNP modified (autol LY-DNP), or TNP-modified (autol LY-TNP); cultured autologous melanoma cells, either unmodified (MEL) or DNP-modified (MELDNP); and allogeneic PBL (Allo LY).

5 Cultures were pulsed with  $^{125}$ IUDR on day 6.

Figure 7 displays responses of CD8+ and CD4+ T cells to DNP-modified autologous cells. Expanded T cells were separated into CD8-enriched or CD4-enriched populations by positive panning. Then they were tested for

10 proliferative response to autologous PBL, either unmodified (autol LY), DNP-modified (autol LY-DNP), and to cultured autologous melanoma cells, either unmodified (MEL) or DNP-modified (MEL-DNP). Cultures were pulsed with  $^{125}$ IUDR on day 6.

15 Figure 8 shows cytokine production by DNP-reactive T cells. The DNP-reactive T cell line ("Parent"), and three subcultures (2F8, 1D7, 1C2), obtained by plating at limiting dilution, were incubated with autologous DNP-modified B lymphoblastoid cells for 18 hours; supernatants were  
20 collected and assayed for gamma interferon (IFN) and IL4.

Figure 9 shows blocking of T cell response by anti-MHC class I monoclonal antibody. Expanded CD8+ T cells were stimulated with autologous DNP-modified B lymphoblastoid cells and the cultures were assayed for gamma  
25 interferon after 18 hours. Stimulator cells were pre-incubated with one of the following: no antibody (none), non-specific mouse IgG (non-specific), monoclonal antibody W6/32 (class I), or monoclonal antibody L243 (class II).

- 14 -

Figure 10 exhibits MHC restriction of T cell response. Expanded CD8+ T cells (HLA-AI, A2, B8, Bw6) were tested for ability to proliferate in response to DNP-modified autologous PBL and to DNP modified allogeneic PBL from four other patients. Three of the allogeneic stimulators were matched at one or more class I loci as shown, and the fourth was completely mismatched (A24, A26, B44, B63). Cultures were pulsed with  $^{125}$ IUDR on day 6.

Figure 11 shows graphs of cytotoxicity of DNP-reactive T cells. Melanoma cells, either autologous (autol) or allogeneic class I-mismatched (allo), were used as targets in a 6-hour  $^{51}$ Cr assay. Effector cells were expanded CD8+, DNP-reactive T cells. Figure 11A - target cells were haptenized with various concentrations of DNBS or TNBS. The effector: target cell ratio was 20:1. Figure 11B - Target cells haptenized with 2.5 mg/ml DNBS or TNBS were mixed with effector cells at a series of effector: target (E:T) ratios.

Figure 12 displays a graph of the percentage of patients tumor free in the months following surgery treated with DNP vaccine and non-haptenized control vaccine.

Figure 13 shows the HPLC fractions which were pooled into five groups of ten fractions each. Peptides derived from dinitrophenyl modified melanoma cells (DNP-MEL) or dinitrophenyl modified B cells (DNP-LY) were stimulatory in pool 2.

Figure 14 displays an inflamed subcutaneous melanoma nodule from DNP-vaccine immunized patient expresses mRNA for IFN $\gamma$  and IL10. Figure 14-1 shows mRNA for

- 15 -

cytokines determined by RT-PCR (lane 1 = size marker; 2 =  $\beta$ -actin; 3 = IFN $\gamma$ , 4 = IL4; 5 = IL10); Figure 14-2 is an H&E stained section of the subcutaneous lesion (400X).

Figure 15 exhibits a lymph node metastasis from an  
5 unimmunized patient expresses mRNA for IL10 but not IFN $\gamma$ .

Figure 15-1 shows mRNA for cytokines determined by RT-PCR (lane 1 = size marker; 2 =  $\beta$ -actin; 3 = IFN $\gamma$ ; 4 = IL4; 5 = IL10); Figure 15-2 is an H&E stained section of the lymph node metastasis (400X).

10 Figure 16 is a gel of IL10 mRNA expressed in human melanoma metastases. mRNA for cytokines was determined by RT-PCR (lane 1 = size marker; C = IL10 cDNA control; 1-7 = patient samples).

Figure 17 is a gel of IL10 mRNA expressed by the  
15 melanoma cells. Figure 17 shows IL10 mRNA expression by RT-PCR from representative tumor biopsy and derived cell line (lane 1 = size marker; 2 = IL10 cDNA; 3 = tumor biopsy; 4 = tumor line).

Figure 18 is an *in-situ* RT-PCR from a paraffin  
20 section of a non-inflamed melanoma biopsy (A=100x, B=400x).

#### DETAILED DESCRIPTION OF THE INVENTION

The present invention is directed to cancer immunotherapy. A novel tumor composition and methods of treating cancer are included in the scope of the invention.

25 The present invention is directed for use in treating cancer, including metastatic and primary cancers. Cancers treatable with the present invention include the

- 16 -

following non-limiting examples: melanoma, breast, lung, colon, breast, kidney, and prostate. Mammals, particularly humans, having metastatic cancer may be treated with the compositions and methods of the present invention.

5           The compositions of the present invention are prepared from a tumor cell or tumor cell extract. A tumor cell may be a malignant or pre-malignant cell of any type of cancer. In accordance with the present invention, pre-malignant refers to any abnormal cell suggestive of a cancer  
10 cell, which is not yet a cancer cell; such as and not limited to dysplastic changes in cervical cells which ultimately lead to cervical cancer, and dysplastic nevi which are abnormal skin cells which lead to melanoma. The tumor cells and extracts preferably originate from the type  
15 of cancer which is to be treated. The tumor cells and extracts may be, and are not limited to, autologous and allogenic cells dissociated from biopsy specimens or tissue culture, as well as stem cells and extracts from these sources. Preferably, the cells and extracts are autologous.  
20 Tumor cell extracts of the present invention may be a peptide isolated from a hapten modified cancer cell or a cell membrane isolated from a hapten modified cancer cell.

For purposes of the present invention, peptides  
25 are compounds of two or more amino acids and includes proteins. Peptides will preferably be of low molecular weight, of about 1,000 kD to about 10,000 kD, more preferably about 1,000 to about 5,000, which are isolated

- 17 -

from a haptenized tumor cell and which stimulate T cell lymphocytes to produce gamma interferon. T cells are lymphocytes which mediate two types of immunologic functions, effector and regulatory, secrete proteins (lymphokines), and kill other cells (cytotoxicity). Effector functions include reactivity such as delayed hypersensitivity, allograft rejection, tumor immunity, and graft-versus-host reactivity. Lymphokine production and cytotoxicity are demonstrated by T cell effector functions.

Regulatory functions of T cells are represented by their ability to amplify cell-mediated cytotoxicity by other T cells and immunoglobulin production by B cells. The regulatory functions also require production of lymphokines. T cells produce gamma interferon ( $\text{IFN}\gamma$ ) in response to an inducing stimulus including and not limited to mitogens, antigens, or lectins. The peptide may preferably be about 8 to about 20 amino acids, in addition the peptide is preferably be haptenized. Peptides may be isolated from the cell surface, cell interior, or any combination of the two locations. The extract may be particular to type of cancer cell (versus normal cell). The peptide of the present invention includes and is not limited to a peptide which binds to the major histocompatibility complex, a cell surface-associated protein, a protein encoded by cancer oncogenes or mutated anti-oncogenes.

The cancer cell membrane of the present invention may be all or part of a membrane from a membrane isolated from a haptenized cancer cell. In accordance with the

- 18 -

definition of cancer cell membrane as set forth for the present invention, a cancer cell membrane may be isolated then haptenized, alternatively, a cancer cell may be haptenized and the membrane subsequently isolated therefrom.

5           The cell extracts are able to stimulate T cells. Stimulation for purposes of the present invention refers to proliferation of T cells as well as production of cytokines by T cells, in response to the cell extract. Membranes and proteins isolated from hapten modified tumor cells and  
10 proteins each independently have the ability to stimulate T cells. Proliferation of T cells may be observed by uptake by T cells of modified nucleic acids, such as and not limited to <sup>3</sup>H thymidine, <sup>125</sup>IUDR (iododeoxyuridine); and dyes such as 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium  
15 bromide (MTT) which stains live cells. In addition, production of cytokines such as and not limited to IFN $\gamma$ , tumor necrosis factor (TNF), and IL-2. Production of cytokines is preferably in an amount of greater than 15 picograms/ml, more preferably about 20 to about 30  
20 picograms/ml, even more preferably about 50 picograms/ml.

          Preferably, the tumor cell extract comprises cellular materials which are unique, or substantially specific to, a particular type of cancer. The tumor cells of the present invention may be live cells. The tumor cells  
25 and extracts of the present invention may be irradiated prior to use. Tumor cells or extracts are irradiated at about 2500 cGy to prevent the cells from growing after injection.



- 19 -

The compositions of the invention may be employed in the method of the invention singly or in combination with other compounds, including and not limited to other compositions of the invention. Accordingly, cancer cells and cancer cell extracts may be used alone or co-administered. For purposes of the present invention, co-administration includes administration together and consecutively. In addition, the cancer cell membrane may be co-administered with the peptide. Further, the cancer cells and/or extracts may be co-administered with other compounds including and not limited to cytokines such as interleukin-2, interleukin-4, gamma interferon, interleukin-12, GM-CSF. The tumor cells and extracts of the invention may also be used in conjunction with other cancer treatments including and not limited to chemotherapy, radiation, antibodies, oligonucleotide sequences, and antisense oligonucleotide sequences.

The compositions of the invention may be administered in a mixture with a pharmaceutically-acceptable carrier, selected with regard to the intended route of administration and the standard pharmaceutical practice. Dosages may be set with regard to weight, and clinical condition of the patient. The proportional ratio of active ingredient to carrier naturally depend on the chemical nature, solubility, and stability of the compositions, as well as the dosage contemplated. Amounts of the tumor cells and extracts of the invention to be used depend on such factors as the affinity of the compound for cancerous cells,

- 20 -

the amount of cancerous cells present and the solubility of the composition. The compounds of the present invention may be administered by any suitable route, including inoculation and injection, for example, intradermal, intravenous,  
5 intraperitoneal, intramuscular, and subcutaneous.

The compositions of the present invention may be administered alone or will generally be administered in admixture with a pharmaceutical carrier selected with regard to the intended route of administration and standard  
10 pharmaceutical practice.

The composition of the present invention is a therapeutically effective amount of a composition selected from the group consisting of live tumor cells, tumor cell extracts, such as a peptide and a cancer cell membrane, and  
15 a mixture of tumor cells and one or more tumor cell extracts. The composition may be mixed with an immunological adjuvant and/or a pharmaceutically acceptable carrier. Any known aqueous vehicle useful in drug delivery, such as and not limited to saline, may be used in accordance  
20 with the present invention as a carrier. In addition, any adjuvant known to skilled artisans may be useful in the delivery of the present invention. Adjuvants include and are not limited to *Bacillus Calmette-Guerin (BCG)*; cytokines, such as and not limited to interleukin-12,  
25 interleukin-2; and synthetic adjuvants such as and not limited to QS-21, (Cambridge Biotech, Worcester, MA) disclosed by Livingston et al., *Vaccine* 1994 12:1275, the disclosure of which is incorporated herein by reference in

- 21 -

its entirety. In the case where the cells and cell extracts are irradiated and haptenized, the cells may be conjugated to a hapten and then irradiated. Alternatively, the cells may be irradiated then conjugated to a hapten. In either  
5 case, the extracts are subsequently purified and then may also be irradiated and/or haptenized. To irradiate and haptenize the extracts, either method may be performed first, followed by the other method.

Alternatively, the tumor cells or tumor cell  
10 extracts may be added to antigen presenting cells. The cancer cell extract may be used to treat cancer together with another cell type, an antigen presenting cell, selected from the group consisting of autologous cultured macrophages and autologous cultured dendritic cells. Macrophages are  
15 any large ameboid mononuclear cell, regardless of origin, such as and not limited to histiocytes and monocytes, which phagocytose, i.e. engulf and destroy, other cells, dead tissue, degenerated cells, and the like. Macrophages are antigen presenting cells, which present antigens, including  
20 tumor antigens, to cells including T cells. Dendritic cells are also antigen presenting cells and appear to be closely related to macrophages, however, dendritic cells are more efficient antigen presenting cells than macrophages. They are potent stimulators of T cells and may be isolated from a  
25 variety of body organs and tissues including and not limited to blood, skin (where dendritic cells are referred to as Langerhans cells), lymphoid tissues.

- 22 -

The antigen presenting cells with peptide or membrane bound thereto, for example, may be used to immunize patients. The patient's blood is obtained and macrophages or dendritic cells are extracted therefrom. High

5 concentrations of the peptide (about 1 ng/ml to about 1  $\mu$ g/ml, preferably about 10 ng/ml to about 100 ng/ml), or membrane (about  $10^5$  to about  $10^7$  cell equivalents, cell equivalents are in relation to the number of starting cells) are incubated with the cells overnight or for about 8 hours.

10 In the case of incubating with membranes, the membranes are phagocytized by the macrophages or dendritic cells. The macrophages or dendritic cells which have phagocytized the membranes are used to immunize the patient, Grabbe, S., et al., *Immunology Today* 1995 16:117-121, the disclosure of

15 which is incorporated herein by reference in its entirety.

In a preferred embodiment of the invention, the composition comprises a vaccine consisting of about  $10 \times 10^6$  to about  $25 \times 10^6$ , more preferably about  $5 \times 10^6$  to about  $25 \times 10^6$ , live, irradiated, tumor cells suspended in a

20 pharmaceutically acceptable carrier or diluent, such as and not limited to Hanks solution, saline, phosphate-buffered saline, and water, to which is added an immunological adjuvant, such as and not limited to *Bacillus Calmette-Guerin* (BCG). The tumor cells and extracts may be

25 conjugated to a hapten. The mixture is injected intradermally into 3 contiguous sites per administration on the upper arms or legs, excluding limbs ipsilateral to a lymph node dissection.

- 23 -

Patients may be immunized to the chemical dinitrophenyl (DNP) by application of dinitrofluorobenzene (DNFB) to the skin. Two weeks later, the patients are injected with a vaccine, which may include irradiated cells  
5   hapttenized to DNP. The vaccine is reinjected every 4 weeks for a total of eight treatments. The drug cyclophosphamide (CY) may be administered 3 days prior to each vaccine administration to augment the immune response to the tumor cells. A non-hapttenized form of the vaccine may be  
10   similarly administered.

The vaccine of the present invention may be hapttenized or non-hapttenized. The hapttenized, or chemically-linked, form of the vaccine may include a tumor cell hapttenized to dinitrophenyl (DNP) for example. Other  
15   hapttens include and are not limited to trinitrophenyl (TNP) and N-iodoacetyl-N'-(5-sulfonic 1-naphtyl) ethylene diamine (AED). A vaccine of tumor cell extracts may similarly be hapttenized. In the case of hapttenized cancer cell extracts, the extracts, a peptide, and a cancer cell membrane, are  
20   isolated from hapttenized cancer cells. The present invention also contemplates a non-hapttenized vaccine of tumor cells and/or cell extracts.

In the methods of the present invention, a method of treating a patient suspected of having cancer, comprises  
25   administering a pharmaceutically acceptable amount of cyclophosphamide, a pharmaceutically acceptable amount of a composition selected from the group consisting of live tumor cells, tumor cell extracts, and a mixture of tumor cells and

- 24 -

tumor cell extracts. Where the composition is a cancer cell extract, the extract may be a peptide or a membrane isolated from a haptenized cancer cell. The composition may be mixed with an immunological adjuvant and/or a pharmaceutically acceptable carrier. The haptenized vaccine may optionally be followed by administration of a pharmaceutically acceptable amount of a non-haptenized vaccine. A non-haptenized vaccine may also be administered in accordance with the methods of the present invention.

10           The vaccine of the present invention may comprise tumor cells and/or tumor cell extracts. The tumor cells for use in the present invention may be prepared as follows. Tumor masses are processed as described by Berd et al. (1986), *supra*, incorporated herein by reference in its  
15   entirety. The cells are extracted by enzymatic dissociation with collagenase and DNase by mechanical dissociation, frozen in a controlled rate freezer, and stored in liquid nitrogen until needed. On the day that a patient is to be skin tested or treated, the cells are thawed, washed, and  
20   irradiated to about 2500 R. They are washed again and then suspended in Hanks balanced salt solution without phenol red. Conjugation of the prepared cells with DNP is performed by the method of Miller and Claman, *J. Immunol.*, 1976, 117, 1519, incorporated herein by reference in its  
25   entirety, which involves a 30 minute incubation of tumor cells with DNFB under sterile conditions, followed by washing with sterile saline.

- 25 -

Cancer cells of a patient may be conjugated to a hapten by isolating the membranes and modifying the membranes or by conjugating the cells to a hapten without first isolating the membranes.

5           A cancer cell membrane may be prepared by isolating membranes from non-modified preparation of cancer cells of a patient. Cells are suspended in about five volumes of about 30 mM sodium bicarbonate buffer with about 1 mM phenyl methyl sulfonyl fluoride and disrupted with a  
10 glass homogenizer. Residual intact cells and nuclei are removed by centrifugation at about 1000 g. The membranes are pelleted by centrifugation at 100,000 g for 90 minutes. The membranes are resuspended in about 8% sucrose and frozen at about -80°C until needed. To a suspension of membranes  
15 (about 5,000,000 cell equivalents/ml), about 0.5 ml of 1 mg/ml dinitrofluorobenzene (DNFB) is added for about 30 minutes. Similarly, other haptens such as and not limited to trinitrophenyl and N-iodoacetyl-N'-(5 sulfonic 1-naphtyl) ethylene diamine may be used. Excess DNP is removed by  
20 dialyzing the membranes against about 0.15 M PBS for about three days. The membranes are pelleted.

Alternatively, the cancer cell extract, the peptide or the membrane, may be prepared by modifying cancer cells of a patient with a hapten such as dinitrophenyl and  
25 then preparing membranes therefrom. Cancer cells of a patient are obtained during biopsy and frozen until needed. About 100 mg of DNFB (Sigma Chemical Co., St. Louis, MO) was dissolved in about 0.5 ml of 70% ethanol. About 99.5 ml of

- 26 -

PBS was added. DNFB concentration should be about 152 mg/0.1 ml. The solution was stirred overnight in a 37 °C water bath. The shelf life of the solution is about 4 weeks. The cells were thawed and the pellet was resuspended  
5 in 5X cells/ml in Hanks balanced salt solution. About 0.1 ml DNFB solution was added to each ml of cells and incubated for about 30 minutes at room temperature. Similarly, other haptens such as and not limited to trinitrophenyl and N-iodoacetyl-N'-(5 sulfonic 1-naphtyl) ethylene diamine may be  
10 used. The cells were then washed twice in Hanks balanced salt solution. Cells are suspended in about five volumes of about 30 mM sodium bicarbonate buffer with about 1 mM phenyl methyl sulfonyl fluoride and disrupted with a glass homogenizer. Residual intact cells and nuclei are removed  
15 by centrifugation at about 1000 g. The membranes are pelleted by centrifugation at 100,000 g for 90 minutes. The membranes are resuspended in about 8% sucrose and frozen at about -80°C until needed.

From the DNP modified cells, peptide may be  
20 extracted, some of which are DNP modified as a result of modifying the cells. Protein extraction techniques, known to those of skill in the art, may be followed by antigen assays to isolate antigen(s) effective for patient treatment. The methods of isolating cell extracts are  
25 readily known to those skilled in the art. Briefly, cancerous cells are isolated from a tumor and cultured in vitro. Dinitrophenyl is added to the cultured cells in accordance with the method set forth above. Peptides are



- 27 -

isolated from cells according to an established technique of Rotzschke et al., *Nature*, 1990, 348, 252, the disclosure of which is hereby incorporated by reference in its entirety. The cells are treated with a weak acid. Then they are

5 centrifuged and the supernatants are saved. Fractions containing small peptides are obtained by HPLC, concentrated, and frozen. The fractions are screened for immunological activity by allowing them to bind to autologous B lymphoblastoid cells which are then tested for

10 ability to stimulate melanoma-specific T lymphocytes.

The cells are treated with a weak acid, such as and not limited to trifluoroacetic acid (TFA). The cells are then centrifuged and the supernatant is saved. Compounds having a molecular weight greater than 5,000 were

15 removed from the supernatant by gel filtration (G25 Sepharose, Pharmacia). The remainder of the supernatant is separated on a reversed-phase HPLC column (Superpac Pep S, Pharmacia LKB) in 0.1% trifluoroacetic acid (TFA) using a gradient of increasing acetonitrile concentration; flow rate

20 = 1 ml/min, fraction size = 1 ml. Fractions containing small peptides are obtained by HPLC according to the method of Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (1989), concentrated, and frozen. The fractions

25 are screened for immunological activity by allowing them to bind to autologous B lymphoblastoid cells which are then tested for ability to stimulate melanoma-specific T lymphocytes.

- 28 -

Epstein barr virus (EBV, ATCC CRL-1612, B95-8 EBV transformed leukocytes, cotton top marmoset, *Saguinus oedipus*) is added to B lymphoblastoid cells in culture. The B lymphoblastoid cells are transformed into a B cell tumor  
5 from the patient's own lymphocytes. Melanoma from a metastasis is cultured in RPMI 1640 + 10% fetal calf serum or 10% pooled human serum. The non-adhered cells are washed off with RPMI medium. When the cells are confluent, they are detached with 0.1% EDTA and split into two flasks. This  
10 process continues where the confluent cells are continuously split. To test for gamma interferon production by T cells, lymphocytes from a patient's blood are obtained. The patient's own tumor cells, which have been modified with a hapten, such as DNP, are mixed with the lymphocytes to  
15 stimulate the T cells. Every seven days, interleukin-2 is added. The T cells are expanded by splitting a as disclosed above. The T cells are then restimulated by the hapten modified cells. An enriched population of T cells result which are responsive to the hapten modified cells.

20 Human cancer vaccines have been developed and tested by a number of workers. Although they can sometimes induce weak immunity to a patient's cancer, they rarely cause tumor regression. The development of inflammatory responses in metastatic tumors was surprisingly found with  
25 the DNP-vaccine of the present invention. The tumor becomes reddened, warm and tender. Ultimately, in some cases, the tumor regresses to the extent that the tumor disappears, to the naked eye and microscopically. Microscopically,

- 29 -

infiltration of T lymphocytes into the tumor mass is observed. Therefore, this approach, which increases the inflammatory response and the number and capacity of lymphocytes entering the tumor, is a significant advance in  
5 the art.

The effectiveness of the vaccine may be improved by adding various biological response modifiers. These agents work by directly or indirectly stimulating the immune response. Biological response modifiers of the present  
10 invention include and are not limited to interleukin-12 and gamma interferon. In this embodiment, IL12 will be given following the each vaccine injection. Administration of IL12 to patients with inflammatory responses is believed to cause the T lymphocytes within the tumor mass to proliferate  
15 and become more active. The increased T cell numbers and functional capacity leads to immunological destruction of the tumors. Dosages for IL12 will be prepared in accordance with the dosage indications set forth above.

Patients with metastatic melanoma were treated  
20 using an immunotherapy regimen with the following components: 1) vaccine consisting of autologous tumor cells conjugated to DNP; and 2) low dose cyclophosphamide pretreatment. Patients were evaluated to determine whether tumor regression had occurred, to monitor tumor inflammatory  
25 responses, and to measure delayed type hypersensitivity to autologous melanoma cells, DNFB (the form of DNP used for skin sensitization), DNP-conjugated autologous lymphocytes, diluent (Hanks solution), purified protein derivative (PPD),

- 30 -

and recall antigens (candida, trichophyton, and mumps). Patients who are considered to be deriving benefit (clinical or immunological) from the therapy are continued in the immunotherapy regimen. Subsequent vaccines may be given  
5 without cyclophosphamide. In a similar experiment, Interleukin 2 linked to polyethylene glycol was found to not be effective.

In another embodiment, a vaccine comprising chemical extracts of cancer cells conjugated to a hapten and  
10 mixed with an immunological adjuvant, such as *Bacillus Calmette-Guerin*, BCG, is used.

In the present invention, biopsies from human melanoma metastases were examined for expression of cytokine mRNA using RT-PCR. mRNA for IFN $\gamma$  is found in post-DNP-  
15 vaccine, inflamed metastases, but only rarely in pretreatment metastases, even those containing large numbers of residual lymph node lymphocytes. Moreover, the Type II cytokine, IL10, is found in almost all melanoma metastases and appears to be produced by the melanoma cells themselves.

20 Patients with metastatic melanoma treated with an autologous, DNP-modified vaccine develop inflammatory responses at tumor sites. Histologically, these inflamed lesions are characterized by T cell infiltration which is sometimes associated with tumor cell destruction. In the  
25 present invention, biopsy specimens of 8 subcutaneous metastases that had developed inflammation following vaccine treatment were tested for expression of mRNA for IFN $\gamma$ , IL4, TNF, and IL10. Post-vaccine, inflamed biopsies contained

- 31 -

mRNA for IFN $\gamma$  (5/8), IL4 (4/8) or both (3/8), and for TNF (4/7). In contrast, IFN $\gamma$  mRNA was detected in only 1/17 and TNF mRNA in 2/16 control specimens (pre-treatment lymph node metastases or non-inflamed subcutaneous metastases). mRNA  
5 for IL10, a cytokine with anti-inflammatory properties, was detected in 24/25 melanoma metastases and was independent of lymphoid content; *in situ* PCR confirmed that melanoma cells were the major source. These findings provide a new parameter by which to measure the effects of cancer  
10 immunotherapy.

The present invention is aimed at analyzing freshly obtained metastatic melanoma biopsies for the presence of cytokine mRNA which correlates with a productive immune response at the tumor site. The expression of IFN $\gamma$   
15 or IL4 mRNA is characteristic of melanoma metastases that have developed an inflammatory response following administration of DNP-modified autologous vaccine. On the other hand, expression of IL10 mRNA is independent of an inflammatory response and seen in nearly all melanoma biopsy  
20 specimens. Examination of cell lines derived from melanoma biopsies as well as *in situ* PCR analysis demonstrated that the source of IL10 is melanoma cells themselves rather than the associated lymphocytes.

Perhaps the most important finding of this work is  
25 the negative one: mRNA for IFN $\gamma$  and IL4 generally is not found in melanoma metastases from untreated patients, nor in metastatic masses that contain large numbers of lymph node lymphocytes. This provides a low background activity of *in*

- 32 -

situ cytokine production against which to compete melanoma tissues whose T cell population has been altered by immunotherapy. Moreover, it underscores an important biological point: T cells extracted from melanoma nodal  
5 metastases probably represent the residua of the original lymph node population rather than lymphocytes that have actually infiltrated the tumor as a result of their recognition of melanoma antigens. Since they are not antigen-activated, they have received no stimulus to produce  
10 IFN $\gamma$  or IL4.

In contrast, biopsy specimens obtained following administration of DNP-vaccine typically expressed mRNA for IFN $\gamma$ . However, DNP-vaccine-induced inflammatory responses cannot be characterized as Type I since some of these  
15 samples contained IL4 as well. Given the sensitivity of PCR-based mRNA analysis, such a pattern could be produced by a small focus of IL4-producing T cells in the midst of a T cell infiltrate that is predominantly IFN $\gamma$ -producing. On the other hand, the presence of mRNA for IFN $\gamma$  and IL4 could  
20 signify the presence of T cells that produce both cytokines - so-called TH<sub>0</sub> cells (Lee et al, *Eur. J. Immunol.* 1992 22:1455-1459). Resolution of this issue will require analyses that allow correlation of mRNA expression with morphology, such as in situ PCR. Whatever the results,  
25 these findings suggest that measured of intra-tumor cytokine production may be an important parameter to measure in patients undergoing immunotherapy.

- 33 -

The present invention strongly suggest that the source of IL10 mRNA is the melanoma cells themselves, rather than the associated lymphocytes. Strong IL10 mRNA bands were detected in 24/25 biopsies, and its expression was  
5 independent of the number of associated lymphocytes or the presence of DNP-vaccine-induced inflammation. Moreover, *in situ* PCR clearly showed IL10 mRNA within melanoma cells. Cell lines derived from the biopsy material expressed IL10 mRNA and produced IL10 as measured by ELISA.

10           The physiologic significance of IL10 production in melanoma tissues is not clear. IL10 is known to be an anti-inflammatory cytokine with ability to inhibit T cell proliferation and IL2 production (Jinquan, T., et al., *J. Immunol.* 1993 151:4545-4551) and delayed type  
15 hypersensitivity (Lee, *supra*), probably by reducing macrophage costimulatory function. Thus IL10 could suppress the activation and proliferation of melanoma-reactive T cells that have infiltrated the tumor site. However, IL10 recently has been shown to be a chemoattractant for CD8+ T  
20 cells (Jinquan, *supra*); this property could account for the predominance of CD8+ cells in DNP-vaccine-induced lymphoid infiltrates. In either case, modulation of IL10 production at the tumor site may have important consequences for the tumor-host relationship.

25           The scope of the present invention also includes a method of screening for cytokine production by a tumor to determine the efficacy of an autologous, irradiated hapten conjugated cell composition in a patient suspected of having

- 34 -

cancer, said method comprising administering said hapten conjugated composition to said patient; obtaining a sample comprising nucleic acids from a patient tissue sample; amplifying nucleic acids specific for a cytokine or  
5 amplifying a signal generated by hybridization of a probe specific to a cytokine specific nucleic acid in said tissue sample; and detecting the presence of the amplified nucleic acids or the amplified signal wherein the presence of amplified nucleic acids or amplified signal indicates  
10 cancer, wherein the presence of amplified nucleic acids or amplified signal from said patient tissue sample indicates efficacy of said hapten conjugated composition.

The tissue sample may be a malignant or pre-malignant tumor, a melanoma tumor for example, or a  
15 subcutaneous inflammatory metastatic melanoma, for example. In addition, a tissue sample may be a solid or liquid tissue sample such as and not limited to all or part of a tumor, saliva, sputum, mucus, bone marrow, serum, blood, urine, lymph, or a tear from a patient suspected of having cancer.

20 Nucleic acids, such as DNA (including cDNA) and RNA (including mRNA), are obtained from the patient tissue sample. Preferably RNA is obtained from a tissue sample. Total RNA is extracted by any method known in the art such as described in Sambrook et al., *Molecular Cloning: A*  
25 *Laboratory Manual* (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1989), incorporated herein by reference in its entirety.



- 35 -

Nucleic acid extraction is followed by amplification of the same by any technique known in the art. The amplification step includes the use of at least one primer sequence which is complementary to a portion of a  
5 cytokine specific sequence. Cytokine specific sequences are defined for purposes of the present invention to include (and are not limited to) all or part of sequences which encode IFN $\gamma$ , TNF, IL-2, IL-12, and IL-13. Generally, the primer sequence is about 21 nucleotides to about 33  
10 nucleotides, preferably about 21 nucleotides, about 31 nucleotides, 32 nucleotides, and about 33 nucleotides in length.

Primer sequences useful in the amplification methods include and are not limited to  $\beta$  actin, SEQ ID NOS:  
15 1 and 2; IFN $\gamma$ , SEQ ID NOS: 3 and 4; IL4, SEQ ID NOS: 5 and 6; IL10, SEQ ID NOS: 7 and 8; and TNF, SEQ ID NOS: 9 and 10.

Where a template dependent process of amplification uses a pair of primers, one primer of the pair may comprise oligonucleotides which are complementary to  
20 nucleic acid sequences which encode cytokine specific proteins. The one primer of the pair may be selected from the group consisting of SEQ ID NOS: 1 to 10.

Alternatively, each of the two oligonucleotides in the primer pair may be specific to a nucleic acid sequence  
25 which encodes a cytokine. The primers may be designed to be complementary to separate regions of a cytokine sequence for example. By separate regions is meant that a first primer is complementary to a 3' region of a cytokine sequence and a

- 36 -

second primer is complementary to a 5' region of a cytokine sequence. Preferably, the primers are complementary to distinct, separate regions and are not complementary to each other. The primers of SEQ ID NOS: 1-10 are merely exemplary  
5 of the primers which may be useful in the present invention.

When an amplification method includes the use of two primers, such as the polymerase chain reaction, the first primer may be selected from the group consisting of SEQUENCE ID NOS: 1, 3, 5, 7, and 9, and the second primer  
10 may be selected from the group consisting of SEQUENCE ID NOS: 2, 4, 6, 8, and 10. Any primer pairs which transcribe nucleic acids toward each other and which are specific for cytokines may be used in accordance with the methods of the present invention.

15 Total extraction of RNA is preferably carried out. As used herein, the term "amplification" refers to template-dependent processes and vector-mediated propagation which result in an increase in the concentration of a specific nucleic acid molecule relative to its initial  
20 concentration, or in an increase in the concentration of a detectable signal. As used herein, the term template-dependent process is intended to refer to a process that involves the template-dependent extension of a primer molecule. The term template dependent process refers to  
25 nucleic acid synthesis of an RNA or a DNA molecule wherein the sequence of the newly synthesized strand of nucleic acid is dictated by the well-known rules of complementary base pairing (see, for example, Watson, J. D. et al., In:

- 37 -

Molecular Biology of the Gene, 4th Ed., W. A. Benjamin, Inc., Menlo Park, Calif. (1987) incorporated herein by reference in its entirety). Typically, vector mediated methodologies involve the introduction of the nucleic acid  
5 fragment into a DNA or RNA vector, the clonal amplification of the vector, and the recovery of the amplified nucleic acid fragment. Examples of such methodologies are provided by Cohen et al. (U.S. Pat. No. 4,237,224), Maniatis, T. et al., Molecular Cloning (A Laboratory Manual), Cold Spring  
10 Harbor Laboratory, 1982, each incorporated herein by reference in its entirety.

A number of template dependent processes are available to amplify the target sequences of interest present in a sample. One of the best known amplification  
15 methods is the polymerase chain reaction (PCR) which is described in detail in U.S. Patents 4,683,195, 4,683,202 and 4,800,159, and in Innis et al., *PCR Protocols*, Academic Press, Inc., San Diego CA, 1990, each of which is incorporated herein by reference in its entirety. Briefly,  
20 in PCR, two primer sequences are prepared which are complementary to regions on opposite complementary strands of the target sequence. An excess of deoxynucleoside triphosphates are added to a reaction mixture along with a DNA polymerase (e.g., Taq polymerase). If the target  
25 sequence is present in a sample, the primers will bind to the target and the polymerase will cause the primers to be extended along the target sequence by adding on nucleotides. By raising and lowering the temperature of the reaction

- 38 -

mixture, the extended primers will dissociate from the target to form reaction products, excess primers will bind to the target and to the reaction products and the process is repeated. Preferably a reverse transcriptase PCR  
5 amplification procedure may be performed in order to quantify the amount of mRNA amplified. Polymerase chain reaction methodologies are well known in the art.

Another method for amplification is the ligase chain reaction (referred to as LCR), disclosed in EPA No.  
10 320,308, incorporated herein by reference in its entirety. In LCR, two complementary probe pairs are prepared, and in the presence of the target sequence, each pair will bind to opposite complementary strands of the target such that they abut. In the presence of a ligase, the two probe pairs will  
15 link to form a single unit. By temperature cycling, as in PCR, bound ligated units dissociate from the target and then serve as "target sequences" for ligation of excess probe pairs. U.S. Patent 4,883,750, incorporated herein by  
reference in its entirety, describes an alternative method  
20 of amplification similar to LCR for binding probe pairs to a target sequence.

Qbeta Replicase, described in PCT Application No. PCT/US87/00880, incorporated herein by reference in its entirety, may also be used as still another amplification  
25 method in the present invention. In this method, a replicative sequence of RNA which has a region complementary to that of a target is added to a sample in the presence of

- 39 -

an RNA polymerase. The polymerase will copy the replicative sequence which can then be detected.

An isothermal amplification method, in which restriction endonucleases and ligases are used to achieve  
5 the amplification of target molecules that contain nucleotide 5'-[alpha -thio]triphosphates in one strand of a restriction site (Walker, G. T., et al., *Proc. Natl. Acad. Sci. (U.S.A.)* 1992, 89:392-396, incorporated herein by reference in its entirety), may also be useful in the  
10 amplification of nucleic acids in the present invention.

Strand Displacement Amplification (SDA) is another method of carrying out isothermal amplification of nucleic acids which involves multiple rounds of strand displacement and synthesis, i.e. nick translation. A similar method,  
15 called Repair Chain Reaction (RCR) is another method of amplification which may be useful in the present invention and is involves annealing several probes throughout a region targeted for amplification, followed by a repair reaction in which only two of the four bases are present. The other two  
20 bases can be added as biotinylated derivatives for easy detection. A similar approach is used in SDA.

Cytokine specific sequences can also be detected using a cyclic probe reaction (CPR). In CPR, a probe having a 3' and 5' sequences of non-cytokine specific DNA and  
25 middle sequence of cytokine specific RNA is hybridized to DNA which is present in a sample. Upon hybridization, the reaction is treated with RNaseH, and the products of the probe identified as distinctive products generating a signal

- 40 -

which are released after digestion. The original template is annealed to another cycling probe and the reaction is repeated. Thus, CPR involves amplifying a signal generated by hybridization of a probe to a cytokine specific nucleic acid.

Still other amplification methods described in GB Application No. 2 202 328, and in PCT Application No. PCT/US89/01025, each of which is incorporated herein by reference in its entirety, may be used in accordance with the present invention. In the former application, "modified" primers are used in a PCR like, template and enzyme dependent synthesis. The primers may be modified by labelling with a capture moiety (e.g., biotin) and/or a detector moiety (e.g., enzyme). In the latter application, an excess of labelled probes are added to a sample. In the presence of the target sequence, the probe binds and is cleaved catalytically. After cleavage, the target sequence is released intact to be bound by excess probe. Cleavage of the labelled probe signals the presence of the target sequence.

Other nucleic acid amplification procedures include transcription-based amplification systems (TAS) (Kwoh D., et al., *Proc. Natl. Acad. Sci. (U.S.A.)* 1989, 86:1173, Gingeras T. R., et al., PCT Application WO 88/10315, incorporated herein by reference in their entirety), including nucleic acid sequence based amplification (NASBA) and 3SR. In NASBA, the nucleic acids can be prepared for amplification by standard

- 41 -

phenol/chloroform extraction, heat denaturation of a clinical sample, treatment with lysis buffer and minispin columns for isolation of DNA and RNA or guanidinium chloride extraction of RNA. These amplification techniques involve  
5 annealing a primer which has prostate specific sequences. Following polymerization, DNA/RNA hybrids are digested with RNase H while double stranded DNA molecules are heat denatured again. In either case the single stranded DNA is made fully double stranded by addition of second prostate  
10 specific primer, followed by polymerization. The double stranded DNA molecules are then multiply transcribed by a polymerase such as T7 or SP6. In an isothermal cyclic reaction, the RNAs are reverse transcribed into double stranded DNA, and transcribed once against with a polymerase  
15 such as T7 or SP6. The resulting products, whether truncated or complete, indicate prostate cancer specific sequences.

Davey, C., et al., European Patent Application Publication No. 329,822, incorporated herein by reference in  
20 its entirety, disclose a nucleic acid amplification process involving cyclically synthesizing single-stranded RNA ("ssRNA"), ssDNA, and double-stranded DNA (dsDNA), which may be used in accordance with the present invention. The ssRNA is a first template for a first primer oligonucleotide,  
25 which is elongated by reverse transcriptase (RNA-dependent DNA polymerase). The RNA is then removed from resulting DNA:RNA duplex by the action of ribonuclease H (RNase H, an RNase specific for RNA in a duplex with either DNA or RNA).

- 42 -

The resultant ssDNA is a second template for a second primer, which also includes the sequences of an RNA polymerase promoter (exemplified by T7 RNA polymerase) 5' to its homology to its template. This primer is then extended  
5 by DNA polymerase (exemplified by the large "Klenow" fragment of *E. coli* DNA polymerase I), resulting as a double-stranded DNA ("dsDNA") molecule, having a sequence identical to that of the original RNA between the primers and having additionally, at one end, a promoter sequence.  
10 This promoter sequence can be used by the appropriate RNA polymerase to make many RNA copies of the DNA. These copies can then re-enter the cycle leading to very swift amplification. With proper choice of enzymes, this amplification can be done isothermally without addition of  
15 enzymes at each cycle. Because of the cyclical nature of this process, the starting sequence can be chosen to be in the form of either DNA or RNA.

Miller, H. I., et al., PCT Application WO 89/06700, incorporated herein by reference in its entirety,  
20 disclose a nucleic acid sequence amplification scheme based on the hybridization of a promoter/primer sequence to a target single-stranded DNA ("ssDNA") followed by transcription of many RNA copies of the sequence. This scheme is not cyclic; i.e. new templates are not produced  
25 from the resultant RNA transcripts. Other amplification methods include "race" disclosed by Frohman, M. A., In: *PCR Protocols: A Guide to Methods and Applications* 1990, Academic Press, N.Y.) and "one-sided PCR" (Ohara, O., et



- 43 -

al., *Proc. Natl. Acad. Sci. (U.S.A.)* 1989, 86:5673-5677), all references herein incorporated by reference in their entirety.

Methods based on ligation of two (or more) oligonucleotides in the presence of nucleic acid having the sequence of the resulting "di-oligonucleotide", thereby amplifying the di-oligonucleotide (Wu, D. Y. et al., *Genomics* 1989, 4:560, incorporated herein by reference in its entirety), may also be used in the amplification step of the present invention.

Following amplification, the presence or absence of the amplification product may be detected. The amplified product may be sequenced by any method known in the art, including and not limited to the Maxam and Gilbert method, see Sambrook, *supra*. The sequenced amplified product may then be compared to results obtained with tissue excised prior to vaccine treatment. Tissue samples obtained prior to vaccine treatment should be free of cytokine sequences, particularly IFN $\gamma$ , TNF, IL2, IL12, and IL13. The nucleic acids may be fragmented into varying sizes of discrete fragments. For example, DNA fragments may be separated according to molecular weight by methods such as and not limited to electrophoresis through an agarose gel matrix. The gels are then analyzed by Southern hybridization. Briefly, DNA in the gel is transferred to a hybridization substrate or matrix such as and not limited to a nitrocellulose sheet and a nylon membrane. A labelled probe is applied to the matrix under selected hybridization

- 44 -

conditions so as to hybridize with complementary DNA localized on the matrix. The probe may be of a length capable of forming a stable duplex. The probe may have a size range of about 200 to about 10,000 nucleotides in length, preferably about 200 nucleotides in length. Mismatches such as and not limited to sequences with similar hydrophobicity and hydrophilicity, will be known to those of skill in the art once armed with the present disclosure. Various labels for visualization or detection are known to those of skill in the art, such as and not limited to fluorescent staining, ethidium bromide staining for example, avidin/biotin, radioactive labeling such as <sup>32</sup>P labeling, and the like. Preferably, the product, such as the PCR product, may be run on an agarose gel and visualized using a stain such as ethidium bromide. See Sambrook et al., *supra*. The matrix may then be analyzed by autoradiography to locate particular fragments which hybridize to the probe.

A diagnostic kit for screening for the efficacy of an autologous, irradiated, hapten conjugated cell composition comprising in one or more containers, a pair of primers, wherein one of the primers within said pair is complementary to a cytokine specific sequence, wherein said primer is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, and SEQ ID NO: 10, and a means for visualizing amplified DNA; said kit useful for determining the efficacy of said composition.

- 45 -

The invention is further illustrated by means of the following actual examples 1-8 and 11 and prophetic examples 9-10 and 12-14 which are meant to be illustrations only and are not intended to limit the present invention to 5 these specific embodiments.

#### Example 1

Sixty-four patients were treated with metastatic melanoma using a melanoma vaccine, prepared in accordance with the methods set forth above, preceded by low dose 10 cyclophosphamide (CY) and monitored for immunological effects and anti-tumor activity. On day 0, the patients were given cyclophosphamide 300 mg/M<sup>2</sup> i.v. Three days later, they were injected intradermally with vaccine consisting of 10 x 10<sup>6</sup> to 25 x 10<sup>6</sup> autologous, cryopreserved, irradiated 15 (2500 R) tumor cells mixed with BCG; the tumor cells were obtained by dissociation of metastatic masses enzymatically (collagenase and DNase). This treatment sequence was repeated every 28 days for 8 treatments.

The toxicity of the therapy was limited to a local 20 inflammatory response at the injection site and mild nausea and vomiting following cyclophosphamide administration. There were 40 evaluable patients with measurable metastases; 5 had responses - 4 complete and 1 partial. The median duration of response was 10 months (7-84 + months). One 25 patient continues to be in remission at 11 years. Regression occurred not only in skin and nodal metastases, but also in lung and liver metastases. In 6 additional

- 46 -

patients, an anti-tumor response was observed that seemed peculiar to this vaccine therapy, i.e., the regression of metastatic lesions that appeared after the immunotherapy was begun. In 3 patients this "delayed" regression occurred in  
5 two or more tumors.

Delayed-type hypersensitivity (DTH) to autologous, mechanically-dissociated melanoma cells was detectable in only 16% of patients before treatment, as compared with in 46%, 56% and 73% of patients on days 49, 161 and 217,  
10 respectively. The increases in delayed type hypersensitivity following immunotherapy were statistically significant by a non-independent t-test; day 0 vs. day 49,  $p < 0.001$ ; day 0 vs. day 161,  $p < 0.001$ ; day 0 vs. day 217,  $p = 0.021$ . Overall, 26/43 patients (61%) exhibited a positive  
15 delayed type hypersensitivity response ( $\geq 5$  mm) to autologous melanoma cells at some time point. Patients also developed strong delayed type hypersensitivity to the enzymes used to prepare the tumor cell suspensions: of 24 patients tested for delayed type hypersensitivity with a  
20 mixture of collagenase and DNase (each at 1  $\mu\text{g/ml}$ ) after two vaccine treatments, 21 (88%) had responses  $> 5\text{mm}$ . Anti-tumor responses to the vaccine were strongly associated with delayed type hypersensitivity to mechanically-dissociated, autologous melanoma cells, as indicated by three  
25 observations: 1) 8/10 patients who exhibited tumor regression had positive delayed type hypersensitivity; 2) in post-surgical adjuvant patients, there was a highly significant correlation between the intensity of delayed

- 47 -

type hypersensitivity to autologous melanoma cells and the time to recurrence of tumor ( $r = 0.680$ ,  $p < 0.001$ ); 3) nine patients who developed delayed type hypersensitivity to the autologous melanoma cells in their original vaccine ("old" tumor) developed new metastases ("new" tumor) that did not elicit delayed type hypersensitivity or elicited a much smaller response. The patients were compared to their condition prior to treatment with the vaccine. The patients treated prior to the vaccine study were removed from treatment one to two months prior to starting the vaccine study. Accordingly, the patients were untreated beginning the vaccine study.

In three cases we were able to excise regressing tumors for histological examination; such tumors were characterized by an intense infiltration of lymphocytes. In contrast, tumors excised from these patients before immunotherapy consisted of homogeneous masses of malignant cells without significant lymphocytic infiltration.

This study shows that the use of cyclophosphamide allows the development of an immune response to melanoma-associated antigens in cancer-bearing patients.

#### Example 2

Patients with metastatic melanoma were sensitized to DNP by topical application to the upper arm with 1% dinitrochlorobenzene (DNCB) or dinitrofluorobenzene (DNFB). Two weeks later they were injected with a vaccine consisting of  $10 \times 10^6$  to  $25 \times 10^6$  autologous, irradiated melanoma cells

- 48 -

conjugated to DNP and mixed with BCG. Cyclophosphamide 300 mg/M<sup>2</sup> i.v. was given 3 days before DNCB (or DNFB) or vaccine. Of 4 evaluable patients, 3 have developed a striking inflammatory response in tumor masses after 2 vaccine treatments (8 weeks). Patient #1 developed erythema and swelling in the > 50 large (1-3 cm) dermal metastases on her leg and lower abdomen, followed by ulceration and drainage of necrotic material, and some are beginning to regress. Biopsy showed infiltration with CD4+ CD8+ T lymphocytes. Patient #2 developed erythema and swelling in the skin of her lower abdomen and groin overlying large (8 cm) nodal masses. These have not yet regressed, but have changed in consistency from rockhard to fluctuant. Patient #3 exhibited moderate erythema in the skin overlying 3 subcutaneous metastases. All 3 patients have developed delayed type hypersensitivity to both DNCB and to DNP conjugated autologous lymphocytes.

The patients were compared to their condition prior to treatment with the vaccine. The patients treated prior to the vaccine study were removed from treatment one to two months prior to starting the vaccine study. Accordingly, the patients were untreated beginning the vaccine study.

### Example 3

Fifteen patients (including 3 patients from Example 2) were treated with metastatic melanoma using a novel form of immunotherapy, i.e., tumor cell vaccine conjugated to DNP. Patients were sensitized to DNP by

- 49 -

topical application to the upper arm with 5% dinitrochlorobenzene. Then every 4 weeks they received cyclophosphamide 300 mg/M<sup>2</sup> followed 3 days later by injection of  $10 \times 10^6$  to  $25 \times 10^6$  autologous, irradiated melanoma cells  
5 conjugated to DNP. Patients received 6-8 treatments. Most patients (92%) developed delayed-type hypersensitivity (DTH) to DNP-conjugated autologous lymphocytes or tumor cells (mean DTH = 17mm). The vaccine induced a striking inflammatory response in subcutaneous and nodal metastases  
10 in 11/15 patients, consisting of erythema, swelling, warmth, and tenderness around tumor masses, and, in one case, purulent drainage. Biopsies showed infiltration with lymphocytes, which, by immunopathological and flow cytometric analyses, were mainly CD3+, CD4-, CD8+, HLA-DR+ T  
15 cells. The melanoma cells in these tissues strongly expressed ICAM-1, which serves as an adhesion molecule for T cells. Thus, DNP-vaccine seems to induce a degree of anti-melanoma immunity not seen with previously tested immunotherapy. The patients were compared to their  
20 condition prior to treatment with the vaccine. The patients treated prior to the vaccine study were removed from treatment one to two months prior to starting the vaccine study. Accordingly, the patients were untreated beginning the vaccine study.

#### 25 Example 4

This example examined the therapeutic effects of DNP-vaccine in patients with surgically-resected metastases

- 50 -

and no clinical evidence of metastatic disease. Forty seven patients were sensitized to the hapten, DNFB (dinitrofluorobenzene). Then they were treated by intradermal injection of autologous, irradiated melanoma cells conjugated to DNP. Additional vaccine injections were administered every 28 days for a total of eight treatments. All patients were periodically tested for Delayed Type Hypersensitivity, DTH, responses to autologous melanoma cells, DNP-conjugated autologous lymphocytes, and microbial antigens. In vitro studies were performed with cryopreserved lymphocytes extracted from metastatic tumors and/or separated from peripheral blood.

The graph of Figure 12 compares the percent of patients tumor free in the months following surgery treated with DNP vaccine and non-haptenized control vaccine. The study examined the therapeutic effects of DNP-vaccine in patients with surgically-resected metastases and no clinical evidence of metastatic disease. All patients were sensitized to the hapten, DNFB (dinitrofluorobenzene). Then they were treated by intradermal injection of autologous, irradiated melanoma cells conjugated to DNP. Additional vaccine injections were administered over 28 days for a total of eight treatments. All patients were periodically tested for Delayed Type Hypersensitivity, DTH, responses to autologous melanoma cells, DNP-conjugated autologous lymphocytes, and microbial antigens. In vitro studies were performed with cryopreserved lymphocytes extracted from metastatic tumors and/or separated from peripheral blood.



- 51 -

## DNP-VACCINE THERAPY OF MELANOMA

	DAY OF WEEK	M	W	F	M	T	M	W	TH	M	TH	M	W	M
	DAY OF STUDY	-21	-19	-17	-14	-13	0	2	3	28	31	49	51	56
5	GYCLO PHOSPH AMIDE			X			X			X				REPEAT
10	DNP VACCINE								X		X			CYCLE
	DNFB SENS				X	X								FOR
	DNFB CHALL						X							A
15	APPLY SKIN TESTS	X					X					X		TOTAL
20	READ SKIN TESTS		X					X					X	OF
	OBTAIN PBL	X					X					X		8
	OBTAIN SERUM	X					X					X		VACCINES
25	ROUTINE LABS	X										X		

CY (cyclophosphamide) = 300 mg/M<sup>2</sup> i.v. bolus only before  
first two vaccines

VACCINE = 5 x 10<sup>6</sup> to 20 x 10<sup>6</sup> autologous, irradiated melanoma  
30 cells mixed with BCG

DNFB SENS = 1.0 mg in 0.1 ml acetone-corn-oil applied to  
ventral upper arm

SUBSTITUTE SHEET (RULE 26)

- 52 -

DNFB CHALL = 200  $\mu$ g in 0.1 ml acetone-corn-oil applied to forearm

APPLY SKIN TESTS = autologous melanoma cells, peripheral blood lymphocytes (PBL), peripheral blood lymphocytes conjugated to DNP (PBL-DNP), purified protein derivative (PPD) (skin test for tuberculosis), microbial recall antigens

\*Day 0: PBL, PBL-DNP only

READ SKIN TESTS = mean diameter of induration

10 OBTAIN PBL = 100 cc heparinized blood

ROUTINE LABS = complete blood count (CBC), differential blood count (diff), platelet count (platelets), SMA-12 (panel of routine lab tests, blood urea nitrogen (BUN))

Sensitization to DNP - Patients initially were sensitized to DNP as follows: On day -17, cyclophosphamide, 300 mg/M<sup>2</sup>, was administered as a rapid i.v. infusion. Three days later, on days -14 and -15, patients were sensitized with DNFB (dinitrofluorobenzene): 1 mg DNFB dissolved in acetone-corn oil and applied topically in a volume of 0.1 ml within the confines of a 2 cm diameter steel ring. Two weeks later, patients were tested for reactivity to DNP by topical application of 200  $\mu$ g DNFB and intradermal injection of DNP-conjugated autologous PBL. Cyclophosphamide was reconstituted in sterile water and the proper dosage was administered by rapid i.v. infusion.

Vaccine Preparation - Tumor masses were processed. Cells were extracted by enzymatic dissociation with

- 53 -

collagenase and DNase and by mechanical dissociation, frozen in a controlled rate freezer, and stored in liquid nitrogen until needed. On the day that a patient was to be treated, the cells were thawed, washed, and irradiated to 2500 R.

- 5 Then they were washed again and suspended in Hanks balanced salt solution without phenol red.

Conjugation of melanoma cells with DNP was performed. This involved a 30 minute incubation of tumor cells with dinitrofluorobenzene (DNFB) under sterile  
10 conditions, followed by washing with sterile saline.

The vaccine consists of  $5-20 \times 10^6$  live tumor cells suspended in 0.2 ml Hanks solution. When BCG is added, it consisted of 0.1 ml of a 1:10 dilution of Tice BCG. Each vaccine treatment consisted of three injections into  
15 contiguous sites on the upper arms or legs, excluding limbs ipsilateral to a lymph node dissection.

Study Procedure - On day 0, patients received cyclophosphamide 300 mg/M<sup>2</sup> as a rapid i.v. infusion. Three days later, on day +3, they were injected intradermally with  
20 autologous melanoma vaccine. Additional vaccine injections were administered every four weeks for a total of eight treatments. Cyclophosphamide was given only prior to the first two injections. All vaccines were DNP-conjugated and mixed with *Bacillus Calmette-Guerin* (BCG). BCG is the Tice  
25 strain (substrain of the Pasteur Institute strain) obtained from Organon Teknika Corporation, Durham, NC. The freeze-dried material was reconstituted with 1 ml sterile water and diluted 1:10 in phosphate-buffered saline, pH 7.2; then 0.1

- 54 -

ml was drawn up, mixed with the vaccine and injected. All vaccines were injected into the same site (upper arm or leg).

Immunological evaluation - Skin-testing was performed by the intradermal injection of 0.1 ml of test material on the forearm, and delayed type hypersensitivity was assessed at 48 hours by measuring the mean diameter of induration. Positive reactions were photographed. The following materials were tested: 1)  $1 \times 10^6$  irradiated autologous melanoma cells; 2)  $3 \times 10^6$  autologous peripheral blood lymphocytes, both unconjugated and conjugated to DNP; 3) Hanks solution; 4) PPD-intermediate strength; and 5) microbial recall antigens - Candida, trichophyton, and mumps. Also, contact sensitivity to DNFB was tested by applying 200  $\mu$ g to the skin of the forearm and examining the area for a circle of induration at 48 hours.

All patients had blood collected for separation and cryopreservation of lymphocytes and serum each time skin-testing was performed (see Table 1 for schedule of blood drawing). Periodically, these were tested for: 1) proliferative and cytotoxic response to autologous melanoma cells; and 2) proliferative response to DNP-conjugated autologous lymphocytes.

- 55 -

Duration of Study

1) Patients were treated with eight courses of vaccine which required about eight months. Treatment was then stopped. These patients will be monitored until at least five years has elapsed since their initial surgery.

2) Patients who developed regional recurrence or distant metastases before the completion of eight treatments were taken off the study and treated as clinically indicated (chemotherapy or surgery).

10           The control group consisted of 22 patients with melanoma metastatic to regional lymph nodes. They underwent surgical resection of their disease, at which time they had no clinical evidence of metastatic melanoma. Then, they received treatment with a non-haptenized, autologous  
15 melanoma vaccine. First, they were given cyclophosphamide, 300 mg/M<sup>2</sup>. Three days later they were injected intradermally with the vaccine, which consisted of  $10 \times 10^6$  to  $25 \times 10^6$  irradiated, autologous melanoma cells mixed with BCG. The cyclophosphamide-vaccine treatment was repeated every 28  
20 days. A total of eight treatments was given. The patients were clinically evaluated every two months.

Only 20% of the control patients were cancer-free at two years. In contrast, patients treated with the DNP-vaccine of the invention had significantly higher cancer-free survival as set forth above.

25           The patients who received haptenized vaccine all had melanoma metastatic to regional lymph nodes, but no evidence of distant metastases. Patients in this condition

- 56 -

are routinely treated by surgical resection of the diseased nodes. Surgical resection renders them clinically disease-free, but they have an 80-85% chance of developing metastatic melanoma with two years.

5           The patients in the control group were in the same clinical condition in order to be comparable to the haptenized vaccine group. Thus, the control group also consisted of patients with melanoma metastatic to regional lymph nodes, but no evidence of distant metastases, who had  
10 undergone surgical resection of the diseased nodes. When treatment was initiated with the non-haptenized vaccine, the control patients were clinically disease-free, but as previously noted, 80% developed distant metastases.

          Patients with surgically incurable melanoma were  
15 not selected as controls because such patients have a cure rate approaching zero, and an even shorter survival than patients with resectable lymph node metastases. Moreover, it is not possible in such patients to measure disease-free survival, a parameter that was dramatically prolonged by the  
20 vaccine of the present invention.

          A statistical analysis of the data was performed as follows: Kaplan-Meier plots of disease-free survival and total survival were constructed. The difference between DNP-vaccine patients and control patients was analyzed by  
25 the Mantel log-rank test. These are standard statistical methods for analyzing such data. The difference was highly significant with  $p < .01$ .

- 57 -

Seventeen patients additional were subsequently treated according to the protocol outlined above (the size of the control group was not increased for reasons set forth above). The results maintained statistically significant differences in disease-free survival and total survival.

#### Example 5

Administration of an autologous, dinitrophenyl (DNP)-conjugated melanoma vaccine induces T cell infiltration of metastatic tumors, and prolongs survival of patients who have undergone lymphadenectomy for bulky regional metastases. These effects appear to be due to melanoma-specific T cells. Their generation is contingent upon T cells with specificity for DNP-modified melanoma cells (DNP-MEL).

#### 15 Clinical Protocol

All patients had metastatic melanoma and were undergoing immunotherapy with autologous, DNP-conjugated tumor vaccine, as previously described in Berd, D., et al., *Cancer Res.*, 1991, 51, 273 I, incorporated herein by reference in its entirety. Informed consent was obtained from the patients. Patients were pre-treated with cyclophosphamide 300 mg/M<sup>2</sup>, see Berd et al. (1986) *supra*, and three days later were sensitized to DNFB by topical application of 0.1 ml of a 1 DNFB solution in acetone-corn oil on two consecutive days. Two weeks later patients were again given cyclophosphamide, followed 3 days later by

- 58 -

injection of DNP-conjugated melanoma vaccine. DNP-vaccine was repeated every 28 days. Cyclophosphamide was given prior to the first two cycles. The vaccine consisted of  $10 \times 10^6$  -  $25 \times 10^6$  cryopreserved, autologous, irradiated (2500 R), DNP-conjugated melanoma cells conjugated to DNP mixed with BCG. All tumor preparations contained lymphocytes which were the residua of tumor-infiltrated lymph node tissue. Serum and PBL were collected at the following time points: day 0 (before sensitization), day 14 (2 weeks after DNFB sensitization), day 63 (after 2 vaccines), day 119 (after 4 vaccines), day 175 (after 6 vaccines), and day 231 (after 8 vaccines).

#### Cellular Reagents

PBL were separated by density gradient centrifugation on Ficoll metrizoate. They were suspended in freezing medium (RPMI-1640 (Mediatech, Washington DC) + 1% human albumin + 10 dimethyl sulfoxide) frozen in a controlled-rate freezer, and stored in liquid nitrogen. HLA typing of PBL was performed by the Thomas Jefferson University Hospital Clinical Laboratory.

Melanoma cells were enzymatically extracted from metastatic masses according to the method of Berd, D., et al., (1986) *supra*, incorporated herein by reference in its entirety, and cryopreserved. Cell lines were derived from these suspensions and were maintained in RPMI-1640 with 10% fetal calf serum. Melanoma cell lines from the patients used in this study were distinguished by MHC class I



- 59 -

differences determined by flow cytometric analysis with a panel of monoclonal antibodies obtained from the American Type Culture Collection: (HB82 = HLA-A2, HB122 = HLA-A3, HB164 = HLA-A11,24).

## 5 Hapten Conjugation

PBL were DNP-modified by a 30 minute incubation with aqueous DNFB or DNBS, according to the methods of Miller, S. D. and H. N. Claman, *J. Immunol.*, 1976, 117, 1519 and Geczy, A. F. and A. Baumgarten, *Immunology*, 1970, 19, 10 189, (incorporated herein by reference in their entirety) respectively; the two methods yielded equivalent results. For specificity controls, cells were modified with TNP by incubation with TNBS, or with oxazolone, according to the methods of Fujiwara, H., et al., *J. Immunol.*, 1980, 124, 863 15 and Boerrigter, G. H. and R. J. Scheper, *J. Invest. Dermatol.*, 1987, 88, 3, (incorporated herein by reference in their entirety) respectively. Hapten conjugation was repeated with melanoma cells.

## Delayed-Type Hypersensitivity (DTH)

20 Cryopreserved PBL were thawed, washed, and resuspended in Hanks balanced salt solution. The cells were divided into three groups: unmodified, conjugated to DNP, and conjugated to TNP. After washing,  $1 \times 10^5$  melanoma cells or  $3 \times 10^6$  PBL were suspended in 0.1 ml Hanks solution and 25 injected intradermally on the forearm. DTH was determined

- 60 -

at 48 hours by measuring the mean diameter of induration. The DTH assay was repeated with melanoma cells.

All patients developed DTH to DNP-modified autologous PBL (Figure 1). DTH responses were evident two weeks after topical application of DNFB (day 14), and then remained stable throughout the period of monthly vaccine administration. DNP-conjugated autologous melanoma cell suspensions elicited stronger DTH than DNP-PBL (mean SE: PBL = 13.3 mm  $\pm$  1.3 mm, melanoma cells = 21.9 mm  $\pm$  3.6 mm;  $p < 0.01$ ). DTH was specific for DNP-modified "self", since autologous PBL conjugated to TNP elicited no response in 50 patients tested.

#### Anti-DNP Antibody

An ELISA was developed by coating microtiter wells with DNP-conjugated PBL. This method was found to be preferable to coating plates with DNP-conjugated albumin because it resulted in lower background readings with serum of pre-immunized patients. DNP-conjugated PBL ( $5 \times 10^5$  in 0.1 ml) were added to each well of 96 flat bottom plate. The cells were fixed to the plate by drying followed by a 5 minute exposure to 100% methanol. Then, the plates were washed five times with phosphate buffered saline + 0.05 % Tween-20. Serial dilutions of test sera were added to the wells and the plate was incubated in a humidified chamber at 37° C for 1 hour. After the incubation, the plate was washed five times, and then horse radish peroxidase-conjugated goat anti-human immunoglobulin (Cappel

- 61 -

Laboratories, Malvern, PA) was added at predetermined optimal dilution. For detecting IgG or IgM antibodies, peroxidase-conjugated goat anti-human IgG or IgM were used, respectively. After a 1 hour incubation at 37° C, the plate  
5 was washed five times and 0.1 ml of substrate (O-phenylenediamine, Sigma Chemical Co., St. Louis, MO) was added to each well followed by 50 µl of 0.12 % hydrogen peroxide. The plate was read in an ELISA plate reader.

The assay was validated using a murine anti-DNP  
10 monoclonal antibody (clone SPE-7; Sigma ImmunoChemicals) and a peroxidase-conjugated antimouse immunoglobulin antibody as the second step reagent. Subsequently, the positive control consisted of a serum sample from a patient who had received multiple injections of DNP-vaccine. Anti-DNP antibody titer  
15 of each serum sample was defined as follows:

(peak OD of sample) X (reciprocal of the dilution having an OD equal to half the peak OD of positive control)

Butler, J. E., *Methods Enzymol.*, 1981, 73, 482.

Anti-DNP antibody developed in 24 out of 27  
20 patients tested (Figure 2). In contrast to DTH, antibody was not induced by DNFB topical application (day 14). In 19 patients, titers increased above pre-immunization levels after two intradermal injections of DNP-conjugated melanoma cells (day 63); in 5 additional patients, significant titers  
25 were found only after 4 to 6 vaccines. In all patients, IgG antibody was detected; anti-DNP IgM was found in only three patients. Anti-DNP antibody cross reacted with TNP, shown

- 62 -

by binding to TNP-modified cells, but not to the unrelated hapten, oxazolone.

#### Development of T cell Lines

PBL ( $1 \times 10^6$ ) were mixed with autologous DNP-  
5 conjugated B lymphoblastoid cells ( $1 \times 10^5$ ) in 24 well flat  
bottom plates in lymphocyte culture medium. After 7 days of  
culture, IL2 100 U/ml (a gift of Cetus Oncology, Emeryville,  
CA) was added. Expanding T cell cultures were maintained in  
medium + IL2 and were split as needed to maintain a  
10 concentration of about  $2 \times 10^6$  cells in a 22 mm diameter  
well. Every 14 days, the cultures were restimulated by  
adding autologous DNP-conjugated B lymphoblastoid cells.  
Phenotypes were determined by flow cytometry with a panel of  
monoclonal antibodies (Becton-Dickinson, San Jose, CA).  
15 Separation of CD8+ and CD4+ T cells was accomplished by  
indirect panning in which T cells coated with anti-CD8 or  
anti-CD4 monoclonal antibodies were adhered to anti-  
immunoglobulin-coated dishes using standard techniques  
according to the methods of Wysocki, L. J. and V. L. Sato,  
20 *Proc. Natl. Acad. Sci. USA*, 1978, 75, 2844, incorporated  
herein by reference in its entirety; the adherent cells were  
isolated and expanded with DNP-modified stimulators and IL2.

Phenotypically homogeneous subpopulations of T  
cells were obtained by culturing at limiting dilution in  
25 round-bottom microtiter wells in lymphocyte culture medium  
containing  $2 \times 10^5$  irradiated allogeneic feeder cells, 200  
U/ml IL2, and phytohemagglutinin. Wells with growing

- 63 -

lymphocyte colonies were screened for ability to proliferate in response to DNP-modified B lymphoblastoid cells.

Positive wells were expanded in IL2 and restimulated with autologous DNP-conjugated B lymphoblastoid cells every 14

5 days.

Lymphoproliferative Responses - PBL were tested as responder cells. They were suspended in lymphocyte culture medium (RPMI-1640, 10% pooled human AB<sup>+</sup> serum, insulin-transferrin-selenite media supplement (Sigma Chemical Co.) 2 mM L-glutamine, 1% non-essential amino acids, 25 mM HEPES buffer, penicillin + streptomycin) and added to 96-well, round bottom microtiter plates at  $1 \times 10^5$  cells/well. Stimulator cells included: 1) autologous or allogeneic PBL, 2) autologous or allogeneic B lymphoblastoid lines made by transfection with Epstein-Barr virus, 3) autologous cultured melanoma cells; they were inactivated by irradiation (5000 R). In most experiments, the responder:stimulator ratio was 1:1. The plates were incubated in a CO<sub>2</sub> incubator at 37°C for 5 days; then the wells were pulsed with <sup>125</sup>I-labeled IUDR (ICN Radiochemical, Costa Mesa, CA) for 6 hours, harvested with an automatic harvesting device, and counted in a gamma counter. The mean of triplicate wells was calculated. Cultured T cells were also tested for a lymphoproliferative response in accordance with the above methods.

25 PBL, obtained and cryopreserved from four patients at the time of maximum DTH reactivity to DNP-modified autologous cells, were thawed and tested for in vitro

- 64 -

proliferative responses. PBL from all four patients proliferated upon stimulation with DNP-modified cells (Figure 3). The kinetics of the development of the proliferative response in one of these patients (DM2) is shown in Figure 4. DNFB application alone (day 14) did not result in detectable numbers of circulating responding cells. Reactive PBL were detected after two injections of DNP-vaccine (day 63) and continued to be detected throughout the 8 months period of vaccine treatment.

10           The proliferative response to DNP-modified cells was specific, since neither unconjugated PBL nor PBL modified with TNP evoked responses (Figure 5). Post-vaccine PBL also proliferated briskly when stimulated with a DNP-modified melanoma cell line derived from autologous tumor  
15 tissue. When stimulated with allogeneic lymphocytes, PBL exhibited the expected mixed lymphocyte reaction which was three to five-fold greater than the DNP responses.

Circulating T lymphocytes from one of these patients (DM2) were expanded in vitro by culture in IL2 and  
20 repeated restimulation with autologous DNP-modified B lymphoblastoid cells. After four weeks of expansion, the T cells were 70% CD3+, CD8+ and 30% CD3+, CD4+. They proliferated when stimulated by autologous, DNP-modified B lymphoblastoid cells or DNP-modified, cultured melanoma  
25 cells, but not by unconjugated autologous cells (Figure 6). These cells were separated by positive panning into CD8-enriched and CD4-enriched populations that were 98% pure as determined by flow cytometry analysis. As shown in Figure

- 65 -

7, both CD4-enriched and CD8-enriched T cells exhibited a proliferative response to DNP-modified autologous B lymphoblastoid cells. However, only CD8+ T cells responded to DNP-modified autologous melanoma cells. This result may have been due to the low constitutive expression (< 5%) of MHC class II by the melanoma cell line.

Expanded T cells were tested for ability to produce cytokines when stimulated with autologous, DNP-modified B lymphoblastoid cells. As shown in Figure 8, they produced gamma interferon but not IL4. To determine whether both CD4+ and CD8+ T cells were involved in the cytokine response, sublines that were obtained by plating T cells at limiting dilution were analyzed. Each of these cultures was homogeneous in respect to expression of CD4 and CD8. Three of these sublines (two CD4+, one CD8+) were tested for cytokine response to DNP-modified B lymphoblastoid cells. All three produced gamma interferon, while none made IL4 (Figure 8).

20 Cytokine Production - T cells were added to round bottom microtiter plates at  $1 \times 10^5$  cells/well. An equal number of stimulators (DNP-modified autologous B lymphoblastoid cells) was added, and supernatants were collected after 18 hours incubation. Commercially available ELISA kits were used to measure gamma interferon (Endogen, Boston, MA; sensitivity = 5 pg/ml) and IL4 (R&D Systems, Minneapolis, MN; sensitivity = 3 pg/ml).

- 66 -

To determine the MHC-dependence of the response, stimulator cells were pre-incubated with monoclonal antibodies to MHC class I (W6/32) or MHC class II (L243) at a concentration of 10 µg/ml for one hour before adding  
5 responder cells. Non-specific mouse immunoglobulin at the same concentration was tested as a negative control.

DNP-reactive CD8+ T cells obtained by panning of the bulk population were able to be maintained in long-term (> 3 months) culture in IL2-containing medium by repeated  
10 stimulation with DNP-modified autologous B lymphoblastoid cells; they retained the stable phenotype, CD3+, CD8+. Two lines of evidence confirmed that their response was MHC class I restricted: 1) Gamma interferon production was blocked by pre-incubation of stimulator cells with anti-  
15 class I framework antibody, but not by anti-class II antibody (Figure 9), 2) The T cells were able to respond to allogeneic DNP-modified stimulators that were matched at one or both HLA-A loci, but not to stimulators that were HLA-A mismatched. As shown in Figure 10, T cells proliferated  
20 upon stimulation with DNP-modified autologous PBL (HLA-A1, A2, B8+, Bw6) and with DNP-modified allogeneic PBL that expressed A1 or A2 or both; no response was elicited by DNP-modified allogeneic stimulators that were A1 and A2-negative.

25 Cytotoxicity - Melanoma targets were labeled for two hours with <sup>51</sup>Cr (Amersham Corp, Arlington Heights, IL), and 2500 cells were added to round-bottom microtiter wells. Then



- 67 -

effector cells were added to achieve a series of E:T ratios. After 6 hours incubation at 37° C supernatants were removed and counted in a gamma counter. Lysis was defined as:

$$([CPM_{\text{test}} - CPM_{\text{spontaneous}}] / [CPM_{\text{total}} - CPM_{\text{spontaneous}}]) * 100.$$

5           The cytotoxicity of the CD8+ T cell line was tested in a <sup>51</sup>Cr-release assay with autologous melanoma cells as targets. To minimize spontaneous <sup>51</sup>Cr release, DNP modification was accomplished with DNBS rather than DNFB. T cells lysed DNP-modified autologous melanoma cells but not  
10 allogeneic (class I-mismatched) melanoma cells (Figures 11a, 11b). There was a direct relationship between susceptibility to lysis and the degree of DNP modification, as determined by the concentration of DNBS used. Neither autologous nor allogeneic targets modified with TNP were  
15 lysed.

#### Example 6

Clinical data was collected to suggest that an autologous, DNP-conjugated melanoma vaccine prolongs  
20 disease-free survival (DFS) and total survival (TS) in melanoma patients with bulky but resectable regional lymph node metastases. Forty-seven patients underwent standard lymphadenectomy with resection of metastatic masses. Tumor cells were enzymatically-dissociated from these tissues and  
25 cryopreserved. Vaccines consisted of 10 x 10<sup>6</sup> to 20 x 10<sup>6</sup> irradiated (2500 cGy) melanoma cells, conjugated to DNP and mixed with BCG. They were injected i.d. every 28 days for a total of 8 treatments. Cyclophosphamide 300 mg/M<sup>2</sup> i.v. was

- 68 -

given 3 days before the first 2 vaccines only. The DFS and TS of these patients were compared with those of 22 melanoma patients with resected nodal metastases treated previously with an unconjugated vaccine, see Example 4. Of 36 patients with stage 3 melanoma (palpable mass in one lymph node region), 22 are disease-free with a median follow-up of 33 months. Kaplan-Meier analysis projects a 3 year DFS and TS of 59% and 71%, respectively. In contrast, the DFS and TS of stage 3 patients treated with unconjugated vaccine was 22% and 27% respectively ( $p = 0.01$ , log-rank test). Of 11 stage 4 patients (palpable mass in two lymph node regions), 5 are NED (no evidence of disease) with a median follow-up of 41 months. For both stage 3 and 4 patients, the highest rate of relapse was in the first 6 months, a time when anti-melanoma immunity might not have yet been established. This experiment will be followed by an accelerated schedule of immunizations to reduce the rate of early relapses and improve the overall clinical outcome. The patients were compared to their condition prior to treatment with the vaccine. The patients treated prior to the vaccine study were removed from treatment one to two months prior to starting the vaccine study. Accordingly, the patients were untreated beginning the vaccine study.

#### Example 7

#### 25 Materials and Methods

Human melanoma tissue and cell lines - Tissue was obtained from patients with metastatic melanoma prior to entry into

- 69 -

the vaccine program and at post vaccine time points. The clinical protocol for the DNP-vaccine administration was performed in accordance with Berd, D., et al., *Cancer Res.* 1991 51:2731-2734. Following surgery, the tumor specimen  
5 was transported to the laboratory, tumor tissue was isolated from surrounding fascia and connective tissue, and pieces of tumor measuring 2-4 mm<sup>3</sup> were snap frozen in liquid nitrogen. Melanoma cell lines from the same specimens were derived from enzyme digests (DNAase and collagenase) of the tumor  
10 and propagated as described by Berd, D., et al. *Cancer Res.* 1986 46:2572-2577.

Isolation of RNA and Amplification via RT-PCR - Total RNA was extracted from frozen tissues by grinding in guanidium isothiocyanate, followed by isolation using CsCl gradient as  
15 described by Lattime, E.C., et al., *J. Immunol.* 1988 144:3422-3428. To minimize the loss of tissue RNA, 15 µg of *E. coli* ribosomal RNA (Sigma Chemical Corp., St. Louis, MO) was added to each sample. Isolated RNA was resuspended in diethylpyrocarbonate treated (DEPC-tx) (Sigma) deionized  
20 distilled water. cDNA synthesis was performed using 10 µg total RNA, Random Primer' (Gibco BRL, Gaithersburg, MD), and RT buffer in DEPC-tx water. This was incubated at 65°C for 10 min and then placed at 4°C. To this, 10 mM DTT (Gibco BRL), 0.5 mM each dATP, dCTP, dTTP, dTTP, (Gibco BRL), and  
25 500 U MMLV-RT (Gibco BRL) was added to achieve a final reaction volume of 50 µl. Samples were incubated at 37°C for 1 hour, then heated to 95°C for 5 min.

- 70 -

For amplification by PCR, 5  $\mu$ l of each cDNA was then added to MicroAmp reaction tubes (Perkin Elmer, Norwalk, CT) containing PCR Reaction buffer, 0.2 mM each dATP, dCTP, dGTP, dTTP, 1.25 U AmpliTaq DNA Polymerase (Perkin Elmer),  $MgCl_2$  concentrations determined to be optimal for each primer pair (final concentrations of 1.5-6.0 mM), and 0.5 mM each of the appropriate primer pairs in a final volume of 50  $\mu$ l. Primer pairs used in this study included  $\beta$ -actin, TNF- $\alpha$ , IL-4, IFN $\gamma$ , South San Francisco, CA) and IL10 (Clontech, Palo Alto, CA).  $\beta$ -actin served for a standard for comparison of relative mRNA expression between samples, as well as a control for RT and PCR reactions. PCR samples were amplified using a GeneAmp System 9600 thermocycler (Perkin Elmer). Each sample was denatured at 94°C for 37 sec, annealed at 55°C for 45 sec, and extended at 72°C for 60 sec for 39 cycles, followed by a 10 min. extension at 72°C.

PCR products and size markers (Novagen, Madison, WI) were separated in a 2.0% agarose gel (FMC BioProducts, Rockland, ME). The gel was stained with ethidium bromide, visualized, and photographed under UV illumination. Electrophoresis of PCR products revealed a band corresponding to the predicted fragment size for each set of primers. Nonreverse transcribed RNA was subjected to amplification by PCR as a control for genomic DNA contamination.

Cryopreserved, enzyme-dissociated cell suspensions of melanoma tissues were found not to be suitable for RNA

- 71 -

analysis- These samples usually expressed mRNA for all cytokines tested, probably a result of activation by the dissociation process.

Histology and In-Situ RT-PCR - Routine H&E staining of

5 representative specimens was done by the Department of Pathology. *In situ* RT-PCR was done on paraffin sections which were permeablized using proteinase K, treated with reverse transcriptase and the resultant IL10 DNA amplified using the same primers as noted above using methodology  
10 according to Bagasra, O., et al., *J. Immunol. Meth.* 1993 158:131-145.

Cytokine mRNA in Inflamed, Post-vaccine biopsies - While metastatic melanoma is characterized by a paucity of lymphocytic infiltration (Elder et al., "The surgical  
15 pathology of cutaneous malignant melanoma." In: W.H. Clark, Jr., et al. (Eds.), *Human Malignant Melanoma*, pp. 100, New York: Grune and Stratton 1979), administration of DNP-vaccine induces T cells infiltration in metastatic masses (Berd et al., 1991 *supra*.) Eight (8) subcutaneous  
20 metastases (from 4 patients) that had developed inflammation following vaccine treatment were studied and compared with 3 subcutaneous metastases excised before vaccine and 4 post-vaccine metastases that failed to develop an inflammatory response. Post-vaccine, inflamed biopsies contained mRNA  
25 for IFN $\gamma$  (5/8), IL4 (4/8) or both (3/8). In contrast, neither IFN $\gamma$  mRNA nor IL4 mRNA was detected in the 7 control specimens. All but one of these 15 tissues expressed mRNA

- 72 -

for IL10. Figure 14 shows cytokine mRNA expression for a representative, T cell-infiltrated post-vaccine biopsy along with the corresponding histology.

Lymph Node Metastases - A group of biopsies of melanoma lymph node metastases was studied as well. Histologically, these lesions are characterized by an abundance of lymphocytes (Figure 15B) that are thought to be the residua of the tumor-infiltrated lymph node lymphocytes (Cardi, et al., *Cancer Res.* 1989 49:6562-6565). Of the 10 lymph node biopsies studied, only one expressed mRNA for IFN $\gamma$ ; this specimen, and one additional specimen, contained mRNA for IL4. However, all 10 specimens contained mRNA for IL10. Figure 15 shows cytokine mRNA expression for a representative lymph node metastasis along with the corresponding histology.

IL10 Production by Melanoma Metastasis and Cell Lines - As indicated above, IL10 mRNA expression was seen in 24/25 melanoma metastases (Figure 16). Since it was independent of IFN $\gamma$  or IL4 mRNA expression and did not correlate with T cell infiltration, melanoma cells, rather than lymphocytes, may be the source of IL10. Two approaches were used to test this hypothesis. First, cell lines derived from two of the metastatic tumors described above were examined. As illustrated in Figure 17A, both the cell lines and the tissue from which they were derived expressed IL10 mRNA.

- 73 -

Both cell lines produced IL10, as determined by assay of culture supernatants after a 72 hour incubation (IL10 concentrations: 760 pg/ml and 10 pg/ml, respectively). Second, IL10 mRNA expression on a tissue section of a melanoma metastasis was studied using *in situ* RT-PCR. As seen in Figure 17B, IL10 mRNA is associated in melanoma cells and not in non-tumor elements.

TNF mRNA is expressed in melanoma metastasis - mRNA for TNF in human colon carcinoma biopsies using *in situ* hybridization (Naylor, M.S., et al., *Cancer Res.* 1990 50:4436-4440), and that resistance to TNF is associated with *in vivo* tumor growth (Lattime, E.C. and Stutman, O., *J. Immunol.* 1989 143:4317-4323). TNF mRNA was detected in 6/23 melanoma specimens. There was an association with DNP-vaccine-induced inflammation: 4/7 T cell-infiltrated post-vaccine biopsies were positive versus 2/16 pre-vaccine or non-infiltrated post-vaccine specimens.

#### Example 8

This example discloses dinitrophenyl modified tumor peptides for cancer immunotherapy.

Epstein barr virus (EBV) was added to B lymphoblastoid cells in culture. The B lymphoblastoid cells were transformed into a B cell tumor from the patient's own lymphocytes. Melanoma from a metastasis was cultured in RPMI 1640 + 10% fetal calf serum or 10% pooled human serum. The non-adhered cells were washed off with RPMI medium.

- 74 -

When the cells were confluent, they were detached with 0.1% EDTA and passaged into two flasks. This process continued for about 10 to about 30 passages. To test for gamma interferon production by T cells, lymphocytes from a patient's blood were obtained. About 1,000,000 lymphocytes were mixed with DNP modified autologous melanoma cells to stimulate T cells. Every seven days, 100 U/ml of interleukin-2 was added. The T cells were expanded by passage as disclosed above. The T cells were then restimulated by the DNP modified autologous melanoma cells. An enriched population of T cells resulted which were responsive to the DNP modified autologous melanoma cells. Stimulation was determined by the amount of gamma interferon production by the T cells. Generally the production of gamma interferon at greater than 15 picograms/ml was considered. These T cells were then used to test the peptide.

Small peptides were extracted from 4 types of cells, all generated from a single patient: 1) B lymphoblastoid cells, 2) B lymphoblastoid cells modified with dinitrophenyl (DNP); 3) cultured melanoma cells, 4) cultured melanoma cells modified with DNP. Cells were suspended in 0.1% trifluoroacetic acid, dounced, sonicated, and centrifuged at 100,000 xg for 90 minutes. Material in the supernatant of molecular weight >10,000 was removed by a Centricon 10 filter. The remaining material was separated on a reversed phase HPLC column. Individual fractions were collected, dried, resuspended in culture medium, and added



- 75 -

to autologous B lymphoblastoid cells, which bound and presented the peptides. These peptide-pulsed B cells were tested for ability to stimulate a T lymphocyte cell line that was specifically sensitized to autologous DNP-modified melanoma cells.

Initially the 50 HPLC fractions (10  $\mu$ l of each sample) were pooled into five groups of ten fractions each. As shown in Figure 13, only peptides derived from DNP-modified melanoma cells (DNP-MEL) or DNP-modified B cells (DNP-LY) were stimulatory, and only pool #2 was positive.

Each of the individual fractions of pool #2 were analyzed by performing the T cell stimulation test with each fraction in pool 2; activity was found only in fractions #17 and #18, and DNP-MEL peptide stimulated two-fold more gamma interferon production than DNP-LY.

These results indicate that a single HPLC fraction of low molecular weight peptide preparation contains the peptide or peptides responsible for stimulation of T cells sensitized to DNP modified melanoma cells.

## 20 Example 9

This example will determine peptide stimulation inhibition by anti-DNP antibody.

The experiment will be identical to that described for Example 8 with one exception. After adding peptide to the B lymphoblastoid cells, and just before adding the responding T cells, varying concentrations (1-100  $\mu$ g/ml) of anti-DNP antibody will be added to different samples. The

- 76 -

anti-DNP antibody may be obtained from the ATCC, hybridoma #CRL-1968, or a similar antibody. If the stimulation is caused by DNP modified peptides, the antibody will inhibit it. It is expected that fractions 17 and 18 will be  
5 inhibited by the antibody.

#### Example 10

Example 10 is expected to determine whether the responding T cells are CD4+ or CD8+.

The experiment will be identical to that described  
10 for Example 8 with one exception. The responding T cells will be fractionated into subsets before being added to the peptide-pulsed B lymphoblastoid cells. This is accomplished by mixing the T cells with magnetic beads coated with either anti-CD4 or anti-CD8 antibodies (obtained commercially from  
15 Immunotech, Inc., Westbrook, Maine). Then the beads, and the cells that have bound to them are removed with a magnet. The non-binding cells are washed in tissue culture medium (RPMI + 10% pooled human serum), counted, and added to the microtiter wells for measurement of stimulation.

#### 20 Example 11

Example 11 discloses dinitrophenyl-modified tumor membranes for cancer immunotherapy.

Membranes from cultured melanoma cells from one patient have been prepared according to the method of Heike  
25 et al., *J. Immunotherapy* 1994 15:165-174, the disclosure of which is incorporated herein by reference in its entirety.

- 77 -

The melanoma cells were conjugated to dinitrophenyl (DNP) according to the methods of Miller and Claman, *J. Immunology* 1976 117:1519-1526, the disclosure of which is incorporated by reference, in its entirety. The cells were suspended in 5 5 volumes of 30 mM sodium bicarbonate buffer with 1 mM phenyl methyl sulfonyl fluoride and disrupted with a glass homogenizer. Residual intact cells and nuclei were removed by centrifugation at 1000 g. Then the membranes were pelleted by centrifugation at 100,000 g for 90 minutes. The 10 membranes were resuspended in 8% sucrose and frozen at -80° until needed. Melanoma cells were similarly prepared for conjugation to dinitrophenyl.

These DNP modified melanoma cell membranes were tested for their ability to stimulate autologous T 15 lymphocytes that had been sensitized to DNP modified intact melanoma cells. This was done by incubating about 100,000 T lymphocytes/well with about 10,000-about 100,000 cell equivalents DNP modified membranes/well, and measuring production of gamma interferon production (greater than 15 20 picograms). This process was repeated by incubating the T lymphocytes with DNP modified melanoma cells. The results revealed that intact melanoma cells and the membranes derived from them were equally effective in stimulating T cells.

25 This experiment, which has been repeated several times (using the same patient sample) with similar results, indicates that DNP modified melanoma membranes can

- 78 -

substitute for DNP modified intact melanoma cells in inducing a T cell response.

#### Example 12

Example 12 will determine if addition of  
5 autologous monocytes or dendritic cells augments the T cell response to tumor membranes.

Autologous monocytes will be isolated as follows. Peripheral blood lymphocytes will be separated from peripheral blood by gradient centrifugation according to the  
10 methods of Boyum, A., *Scand. J. Clin. Lab. Invest.* 21, 1968 Suppl 97:77-89, the disclosure of which is incorporated herein by reference in its entirety. They will be suspended in tissue culture medium (RPMI-1640 + 10% pooled human serum) and added to plastic microtiter wells for about two  
15 hours in order for monocytes to adhere. Then the non-adherent cells will be washed off with culture medium. Various concentrations of GM-CSF (granulocyte macrophage colony stimulating factor, obtained commercially from Immunex, Seattle, WA) will be added to stimulate growth of  
20 the monocytes. After about 2-3 weeks, the monocytes, now considered macrophages, will be removed from the plastic with 0.1% EDTA and added in graded numbers (about 100 to about 10,000/well) to fresh microtiter wells. Graded numbers of membranes, prepared from DNP modified autologous  
25 tumor cells (quantified as cell equivalents), will be added to the adherent macrophage monolayer. After about 6 to about 24 hours, DNP specific autologous T cells will be

- 79 -

added and incubated for an additional 24 hours. Then supernatants will be collected and tested for production of cytokines such as and not limited to gamma interferon, IL2, tumor necrosis factor; or for proliferation or stimulation  
5 of T cells such as by  $^{125}$ IUDR,  $^3$ H thymidine, or with dyes such as MTT. For example,  $^{125}$ IUDR will be added and the cells will be collected on an automatic harvesting device to test for T cell proliferation. Controls will consist of unstimulated T cells and T cells stimulated with membranes in the absence  
10 of macrophages. The ability of autologous dendritic cells to enhance the response to membranes will be tested in the same manner. Dendritic cells will be isolated from peripheral blood mononuclear cells and grown in tissue culture according to the method of O'Doherty, U., et al., *J. Exp. Med.* 1993 178:10678-1078, the disclosure of which is  
15 incorporated herein by reference in its entirety.

### Example 13

Example 13 is expected to determine whether patients who received DNP modified melanoma vaccine manifest  
20 delayed type hypersensitivity (DTH) to autologous DNP-modified melanoma membranes.

The study subjects will be patients who have received repeated doses of DNP modified melanoma cell vaccine. Membranes will be prepared from autologous DNP  
25 modified melanoma cells as described above. Graded numbers of membranes (about 100 to about 10,000 cell equivalents) will be washed in PBS, resuspended in PBS, and injected

- 80 -

intradermally on the forearm. DTH will be measured about 48 hours later as the diameter of cutaneous induration.

Controls will consist of autologous unconjugated melanoma cell membranes and membranes prepared from autologous blood lymphocytes.

#### Example 14

Example 14 is expected to determine whether macrophages or dendritic cells process allogeneic melanoma membranes and present them in an immunogenic manner to T cells syngeneic to those macrophages.

The procedure will be similar to that described for Example 12 with the exception that the stimulating membranes will be prepared from allogeneic DNP conjugated melanoma cells. The hypothesis is that macrophages or dendritic cells from patient A can *in vitro* process membranes obtained from the melanoma cells of patient B. This results in stimulation of T cells from patient A. This experiment may lead to a strategy for allogeneic immunization. DNP modified membranes prepared from a single allogeneic melanoma cell line, or pool of allogeneic cell lines, would be processed by a patient's macrophages or dendritic cells *in vitro*. Those cells would be used for immunization.

- 81 -

The disclosures of each patent, patent application and publication cited or described in this document are hereby incorporated herein by reference, in their entirety.

Various modifications of the invention in addition  
5 to those shown and described herein will be apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims.

- 82 -

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

- (i) APPLICANT: Berd, David;  
Eisenlohr, Lawrence; and  
Lattime, Edmund
- (ii) TITLE OF INVENTION:  
COMPOSITION COMPRISING A TUMOR CELL EXTRACT AND METHOD OF  
USING THE COMPOSITION
- (iii) NUMBER OF SEQUENCES: 10
- (iv) CORRESPONDENCE ADDRESS:
  - (A) ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz &  
Norris
  - (B) STREET: One Liberty Place - 46th Floor
  - (C) CITY: Philadelphia
  - (D) STATE: PA
  - (E) COUNTRY: USA
  - (F) ZIP: 19103
- (v) COMPUTER READABLE FORM:
  - (A) MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
  - (B) COMPUTER: IBM PS/2
  - (C) OPERATING SYSTEM: PC-DOS
  - (D) SOFTWARE: WORDPERFECT 5.1
- (vi) CURRENT APPLICATION DATA:
  - (A) APPLICATION NUMBER: Unknown
  - (B) FILING DATE: June 7, 1995
  - (C) CLASSIFICATION: Unknown
- (vii) PRIOR APPLICATION DATA:
  - (A) APPLICATION NUMBER: 08/203,004
  - (B) FILING DATE: February 28, 1994
- (viii) ATTORNEY/AGENT INFORMATION:
  - (A) NAME: Lori Y. Beardell
  - (B) REGISTRATION NUMBER: 34,293
  - (C) REFERENCE/DOCKET NUMBER: TJU-1582
- (ix) TELECOMMUNICATION INFORMATION:
  - (A) TELEPHONE: (215) 568-3100
  - (B) TELEFAX: (215) 568-3439

## (2) INFORMATION FOR SEQ ID NO: 1:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 21 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: nucleic acids
- (iii) HYPOTHETICAL: No
- (iv) ANTI-SENSE: No
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:  
ATGGATGATG ATATCGCCGC G 21



- 83 -

- (3) INFORMATION FOR SEQ ID NO: 2:  
    (i) SEQUENCE CHARACTERISTICS:  
        (A) LENGTH: 33 base pairs  
        (B) TYPE: nucleic acid  
        (C) STRANDEDNESS: single  
        (D) TOPOLOGY: linear  
  
    (ii) MOLECULE TYPE: nucleic acids  
  
    (iii) HYPOTHETICAL: No  
  
    (iv) ANTI-SENSE: Yes  
  
    (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:  
CTAGAAGCAT TTGCGGTGGA CGATGGAGGG GCC 33
- (4) INFORMATION FOR SEQ ID NO: 3:  
    (i) SEQUENCE CHARACTERISTICS:  
        (A) LENGTH: 21 base pairs  
        (B) TYPE: nucleic acid  
        (C) STRANDEDNESS: single  
        (D) TOPOLOGY: linear  
  
    (ii) MOLECULE TYPE: nucleic acids  
  
    (iii) HYPOTHETICAL: No  
  
    (iv) ANTI-SENSE: No  
  
    (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:  
ATGAAATATA CAAGTTATAT C 21
- (5) INFORMATION FOR SEQ ID NO: 4:  
    (i) SEQUENCE CHARACTERISTICS:  
        (A) LENGTH: 33 base pairs  
        (B) TYPE: nucleic acid  
        (C) STRANDEDNESS: single  
        (D) TOPOLOGY: linear  
  
    (ii) MOLECULE TYPE: nucleic acids  
  
    (iii) HYPOTHETICAL: No  
  
    (iv) ANTI-SENSE: Yes  
  
    (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:  
TTACTGGGAT GCTCTTCGAC CTCGAAACAG CAT 33
- (6) INFORMATION FOR SEQ ID NO: 5:  
    (i) SEQUENCE CHARACTERISTICS:  
        (A) LENGTH: 21 base pairs  
        (B) TYPE: nucleic acid  
        (C) STRANDEDNESS: single  
        (D) TOPOLOGY: linear  
  
    (ii) MOLECULE TYPE: nucleic acids

- 84 -

(iii) HYPOTHETICAL: No

(iv) ANTI-SENSE: No

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:  
ATGGGTCTCA CCTCCCAACT G 21

(7) INFORMATION FOR SEQ ID NO: 6:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 33 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: nucleic acids

(iii) HYPOTHETICAL: No

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:  
TCAGCTCGAA CACTTTGAAT ATTTCTCTCT CAT 33

(8) INFORMATION FOR SEQ ID NO: 7:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 32 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: nucleic acids

(iii) HYPOTHETICAL: No

(iv) ANTI-SENSE: No

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:  
AAGCTGAGAA CCAAGACCCA GACATCAAGG CG 32

(9) INFORMATION FOR SEQ ID NO: 8:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 31 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: nucleic acids

(iii) HYPOTHETICAL: No

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:  
AGCTATCCCA GAGCCCCAGA TCCGATTTTG G 31

- 85 -

## (10) INFORMATION FOR SEQ ID NO: 9:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 21 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: nucleic acids

(iii) HYPOTHETICAL: No

(iv) ANTI-SENSE: No

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:  
ATGAGCACTG AAAGCATGAT C 21

## (11) INFORMATION FOR SEQ ID NO: 10:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 23 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: nucleic acids

(iii) HYPOTHETICAL: No

(iv) ANTI-SENSE: No

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:  
TCACAGGGCA ATGATCCCAA AGT 23

- 86 -

What is claimed is:

1. A composition comprising a therapeutically effective amount of a hapten modified tumor cell extract, said composition stimulates T cell lymphocytes and is  
5 useful for the treatment of cancer.
2. The composition of claim 1 wherein said tumor cell extract is selected from the group consisting of a hapten modified cancer cell membrane, a low molecular weight peptide from a hapten modified cancer cell, an  
10 antigen presenting cell with a low molecular weight peptide from a hapten modified cancer cell bound thereto, and an antigen presenting cell with a hapten modified cancer cell membrane bound thereto.
3. The composition of claim 1 wherein said  
15 tumor cell extract is a low molecular weight peptide from a dinitrophenyl modified cancer cell.
4. The composition of claim 1 wherein said tumor cell extract is a membrane of a dinitrophenyl modified cancer cell.
- 20 5. A composition of claim 1 wherein said tumor cell extract is an antigen presenting cell with a low molecular weight peptide from a hapten modified cancer cell, or a hapten modified cancer cell membrane, bound thereto.
- 25 6. The composition of claim 1 wherein said tumor cell extract is selected from the group consisting of an autologous cell and an allogenic cell.
7. The composition of claim 1 wherein said tumor is selected from the group consisting of melanoma,  
30 breast, lung, colon, breast, kidney, and prostate.

- 87 -

8. The composition of claim 1 wherein said tumor is melanoma.

9. The composition of claim 2 wherein said hapten is selected from the group consisting of 5 dinitrophenyl, trinitrophenyl, and N-iodoacetyl-N'-(5 sulfonic 1-naphtyl) ethylene diamine.

10. The composition of claim 9 wherein said hapten is dinitrophenyl.

11. The composition of claim 1 further comprising an immunological adjuvant.

12. The composition of claim 11 wherein said immunological adjuvant is *Bacillus Calmette-Guerin*.

13. A composition comprising a therapeutically effective amount of a dinitrophenyl modified cancer cell membrane, said composition stimulates T cell lymphocytes and is useful for the treatment of cancer.

14. A composition comprising a therapeutically effective amount of a low molecular weight peptide from a dinitrophenyl modified cancer cell, said composition stimulates T cell lymphocytes and is useful for the treatment of cancer.

15. A method for treating cancer comprising administering to a patient a therapeutically effective amount of cyclophosphamide; administering a therapeutically effective amount of a hapten modified tumor cell extract wherein said extract stimulates T cell lymphocytes.

16. The method of claim 15 wherein said tumor is selected from melanoma, lung, colon, breast, kidney, and prostate.

- 88 -

17. The method of claim 15 useful for the treatment of cancer selected from the group consisting of melanoma, lung cancer, colon cancer, breast cancer, kidney cancer, and prostate cancer.

5 18. The method of claim 15 wherein said tumor cell extract is selected from the group consisting of a hapten modified cancer cell membrane and a low molecular weight peptide from a hapten modified cancer cell.

10 19. The method of claim 18 wherein said hapten is selected from the group consisting of dinitrophenyl, trinitrophenyl, and N-iodoacetyl-N'-(5-sulfonic 1-naphtyl) ethylene diamine.

20. The method of claim 18 wherein said hapten is dinitrophenyl.

15 21. The method of claim 15 wherein said tumor cell extract is a low molecular weight peptide from a dinitrophenyl modified cancer cell.

22. The composition of claim 15 wherein said tumor cell extract is a membrane of a dinitrophenyl  
20 modified cancer cell.

23. The method of claim 15 wherein said tumor cell extract is selected from the group consisting of an autologous cell and an allogenic cell.

24. The method of claim 15 wherein said  
25 therapeutically effective amount of cyclophosphamide comprises administering a dose of about 300 mg/M<sup>2</sup> of cyclophosphamide prior to administration of said composition.

- 89 -

25. The method of claim 15 wherein said composition is mixed with said immunological adjuvant prior to administration.

26. The method of claim 25 wherein said immunological adjuvant is *Bacillus Calmette-Guerin*.

27. The method of claim 15 further comprising sensitizing the patient with a therapeutically effective amount of 1-fluoro-2,4-dinitrobenzene prior to administering cyclophosphamide.

10 28. A method for the treatment of human cancer comprising administering to a patient with a therapeutically effective amount of cyclophosphamide; administering a therapeutically effective amount of a tumor cell extract which stimulates T cell lymphocytes, said  
15 composition mixed with an immunological adjuvant; and administering a therapeutically effective amount of a cytokine selected from the group consisting of interleukin-12, interleukin-2, and interleukin-13.

29. The method of claim 28 wherein said tumor  
20 cell extract is selected from the group consisting of a hapten modified cancer cell membrane and a low molecular weight peptide from a hapten modified cancer cell.

30. The method of claim 29 wherein said hapten is selected from the group consisting of dinitrophenyl,  
25 trinitrophenyl, and N-iodoacetyl-N'-(5-sulfonic 1-naphtyl) ethylene diamine.

31. The method of claim 29 wherein said hapten is dinitrophenyl.

- 90 -

32. The method of claim 28 wherein said tumor cell extract is a low molecular weight peptide from a dinitrophenyl modified cancer cell.

33. The composition of claim 28 wherein said tumor cell extract is a membrane of a dinitrophenyl modified cancer cell.

34. The method of claim 28 wherein said tumor cell extract is selected from the group consisting of an autologous cell and an allogenic cell.

10 35. The method of claim 28 wherein said therapeutically effective amount of cyclophosphamide comprises administering a dose of about 300 mg/M<sup>2</sup> of cyclophosphamide prior to administration of said composition.

15 36. The method of claim 28 wherein said composition is mixed with an immunological adjuvant prior to administration.

37. The method of claim 28 wherein said immunological adjuvant is *Bacillus Calmette-Guerin*.

20 38. The method of claim 28 wherein said tumor is selected from melanoma, lung, colon, breast, kidney, and prostate.

39. The method of claim 28 useful for the treatment of cancer selected from the group consisting of  
25 melanoma, lung cancer, colon cancer, breast cancer, kidney cancer, and prostate cancer.

40. The method of claim 28 further comprising sensitizing the patient with 1-fluoro-2,4-dinitrobenzene prior to administering cyclophosphamide.



- 91 -

41. A method for treating cancer comprising administering to a patient a therapeutically effective amount of cyclophosphamide; administering a therapeutically effective amount of a tumor cell extract which stimulates T 5 cell lymphocytes, said composition mixed with an immunological adjuvant; administering a therapeutically effective amount of a non-haptenized, irradiated composition comprising a tumor cell extract.

42. A method of screening for cytokine 10 production by tumors to determine the efficacy of an autologous, irradiated hapten conjugated cell composition to alleviate cancer in a patient suspected of having cancer, said method comprising:

administering said hapten conjugated composition 15 to said patient;

obtaining a sample comprising nucleic acids from a patient tissue sample;

amplifying nucleic acids specific for a cytokine or amplifying a signal generated by hybridization of a 20 probe specific to a cytokine specific nucleic acid in said tissue sample; and

detecting the presence of the amplified nucleic acids or the amplified signal, wherein the presence of amplified nucleic acids or amplified signal from said 25 patient tissue sample indicates cytokine production and determines efficacy of said hapten conjugated composition.

43. The method of claim 42 wherein said hapten is selected from the group consisting of dinitrophenyl, trinitrophenyl, and N-iodoacetyl-N'-(5-sulfonic 1-naphtyl) 30 ethylene diamine.

44. The method of claim 42 wherein said patient tissue sample is a subcutaneous inflammation.

- 92 -

45. The method of claim 42 wherein said amplification step comprises hybridization to a cytokine specific nucleic acid of at least one oligonucleotide which is complementary to a cytokine specific sequence.

5           46. The method of claim 42 wherein the nucleic acids specific for a cytokine comprise nucleic acids encoding gamma interferon, tumor necrosis factor, interleukin 2, interleukin 12, and interleukin 13.

10           47. The method of claim 42 wherein said amplification step comprises hybridization to a cytokine specific nucleic acid with a pair of primers, wherein one primer within said pair is complementary to cytokine specific sequence.

15           48. The method of claim 42 wherein said amplification step comprises performing a procedure selected from the group consisting of polymerase chain reaction, ligase chain reaction, repair chain reaction, cyclic probe reaction, nucleic acid sequence based amplification, strand displacement amplification, and Q $\beta$  replicase.

25           49. The method of claim 42 wherein said amplification step comprises performing a polymerase chain reaction, wherein said polymerase chain reaction comprises a first primer and a second primer, wherein said first primer is selected from the group consisting of SEQUENCE ID NOS: 1, 3, 5, 7, and 9, and said second primer is selected from the group consisting of SEQUENCE ID NOS: 2, 4, 6, 8, and 10.

- 93 -

50. The method of claim 42 wherein said amplification step comprises performing a polymerase chain reaction wherein said polymerase chain reaction comprises a first primer and a second primer, wherein said first primer 5 is SEQ ID NO: 3 and said second primer is SEQ ID NO: 4.

51. The method of claim 42 wherein said amplification step comprises performing a polymerase chain reaction, wherein said polymerase chain reaction comprises a pair of primers, wherein one primer of said pair is 10 complementary to a cytokine specific sequence.

52. The method of claim 42 wherein the primer that is complementary to a cytokine specific sequence is selected from the group consisting of SEQUENCE ID NOS: 1 to 10.

15 53. The method of claim 47 wherein the primer that is complementary to cytokine specific sequence is selected from the group consisting of SEQ ID NOS: 1 to 10.

54. The method of claim 47 wherein the primer that is complementary to a cytokine specific sequence is 20 SEQ ID NO: 3.

55. The method of claim 42 wherein said patient tissue sample is a tissue selected from the group consisting of a tumor, saliva, sputum, mucus, bone marrow, serum, blood, urine, lymph, and a tear.

25 56. A diagnostic kit for screening for the efficacy of an autologous, irradiated, hapten conjugated cell composition comprising in one or more containers, a pair of primers, wherein one of the primers within said pair is complementary to a cytokine specific sequence, 30 wherein said primer is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4,

- 94 -

SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, and SEQ ID NO: 10, and a means for visualizing amplified DNA; said kit useful for determining the efficacy of said composition.

5           57. The diagnostic kit of claim 56 wherein said means for visualizing amplified DNA is selected from the group consisting of ethidium bromide stain, <sup>32</sup>P, and biotin.

58. The method of claim 42 wherein said patient tissue sample is a melanoma tissue.

10           59. A method of screening for cytokine production by a tumor to determine the efficacy of an autologous, irradiated hapten conjugated cell composition in a patient suspected of having cancer, said method comprising:  
15           obtaining a sample of RNA from a patient tumor sample;  
              reverse transcribing said RNA into DNA;  
              amplifying said DNA with polymerase chain reaction using a pair of primers which are complementary to  
20 separate regions of a cytokine sequence; and  
              detecting the presence or absence of amplified DNA wherein the presence of amplified DNA indicates cytokine production and determines efficacy of said hapten conjugated composition.

25           60. The method of claim 59 wherein the polymerase chain reaction is *in situ* polymerase chain reaction.

## AMENDED CLAIMS

[received by the International Bureau on 18 November 1996 (18.11.96);  
new claims 61-80 added;  
remaining claims unchanged (2 pages)]

61. A composition comprising a hapten modified human tumor cell.
62. A composition of claim 61 wherein said tumor is selected from the group consisting of melanoma, lung, colon, breast, kidney, and prostate.
63. A composition of claim 61 wherein said hapten is selected from the group consisting of dinitrophenyl, trinitrophenyl, and N-iodoacetyl-N' (5 sulfonic 1-naphtyl) ethylene diamine.
64. A composition of claim 61 further comprising an adjuvant.
65. A composition of claim 64 wherein said adjuvant is selected from the group consisting of *Bacillus Calmette-Guerin*, cytokines and QS-21.
66. A composition of claim 61 further comprising a carrier.
67. A composition of claim 66 wherein said carrier is selected from the group consisting of saline and culture medium.
68. A composition comprising a hapten modified human tumor cell wherein said hapten is selected from the group consisting of dinitrophenyl, trinitrophenyl, and N-iodoacetyl-N' (5 sulfonic 1-naphtyl) ethylene diamine and an adjuvant selected from the group consisting of *Bacillus Calmette-Guerin*, cytokines and QS-21.
69. A composition comprising a hapten modified human melanoma tumor cell.
70. A composition comprising a hapten modified human lung tumor cell.
71. A composition comprising a hapten modified human colon tumor cell.
72. A composition comprising a hapten modified human breast tumor cell.
73. A composition comprising a hapten modified human kidney tumor cell.
74. A composition comprising a hapten modified human prostate tumor cell.
75. A composition of claims 69-74 wherein said hapten is selected from the group consisting of dinitrophenyl, trinitrophenyl, and N-iodoacetyl-N' (5 sulfonic 1-naphtyl) ethylene diamine.
76. A composition of claim 75 further comprising a carrier.

-96-

77. A composition of claim 76 wherein said carrier is selected from the group consisting of saline and culture medium.

78. A composition of claim 75 further comprising an adjuvant selected from the group consisting of *Bacillus Calmette-Guerin*, cytokines and QS-21.

79. A composition of claim 78 further comprising a carrier.

80. A composition of claim 79 wherein said carrier is selected from the group consisting of saline and culture medium.


AMENDED SHEET (ARTICLE 19)

STATEMENT UNDER ARTICLE 19

Claims 61-80 are newly added on substitute pages 94/1 and 94/2. Support for the newly added claims may be found in the specification as filed, see for example, page 16, lines 1-2; page 20, lines 11-28; page 23, lines 1-22; page 28, lines 6 and 8; page 63, line 7; page 73, line 26; page 74, line 28.


The claims are believed to be free of prior art.

1/19


**Figure 1**




2/19

**Figure 2**


3/19

**Figure 3**


4/19

**Figure 4**


5/19

**Figure 5**


6/19

**Figure 6**


7/19

**Figure 7**

8/19


**Figure 8**

9/19

**Figure 9**




10/19


**Figure 10**

11/19


Figure 11A



12/19

**Figure 11B**

13/19



**FIGURE 12**

14/19

## T Cell Simulation by Peptides from DNP-modified Melanoma Cells






FIGURE 13

## A. Inflamed Subcutaneous Melanoma Nodule from DNP-Vaccine Immunized Patient

### 1. mRNA by RT-PCR



### 2. H&E Stain, Original Magnification 400X




**FIGURE 14**


16/19

## B. Lymph Node Metastasis from an Unimmunized Patient

### 1. mRNA by RT-PCR



### 2. H&E Stain, Original Magnification 400X



**FIGURE 15**

17/19





FIGURE 16




18/19


# IL10 mRNA is Expressed by Tumor Biopsy and Biopsy-Derived Cell Line

**FIGURE 17**

**A. Original magnification 100X**




**B. Original magnification 400X**



**FIGURE 18**

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US96/09511

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> IPC(6) : Please See Extra Sheet. US CL : Please See Extra Sheet. According to International Patent Classification (IPC) or to both national classification and IPC																				
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) U.S. : 424/85.2, 85.4, 184.1, 185.1, 193.1, 278.1, 520; 435/6, 91.2, 961; 514/2 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Please See Extra Sheet.																				
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>																				
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.																		
X	SIA et al. Studies in the enhancement of tumour immunity by coupling strong antigens to tumour cells ('heterogenization of tumours'). Helper T cell clones against PPD help other T cells mount anti-tumour responses to PPD-coupled tumour cells. Immunol. April 1984, Vol. 51, pages 755-763, see entire document.  KOSUGI et al. Cross-reactivity between haptenic muramyl Di- or Tripeptide derivatives and <i>Mycobacterium bovis</i> BCG: Potential application for enhancing tumor immunity. Infection & Immunity. December 1986, Vol. 54, No. 3, pages 768-773, see entire document.	1-12																		
Y		13-40																		
Y		1-41																		
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.																				
<table border="0"> <tr> <td>* Special categories of cited documents:</td> <td>"T"</td> <td>Inter document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>"A" document defining the general state of the art which is not considered to be of particular relevance</td> <td>"X"</td> <td>document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>"E" earlier document published on or after the international filing date</td> <td>"Y"</td> <td>document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>"&amp;"</td> <td>document member of the same patent family</td> </tr> <tr> <td>"O" document referring to an oral disclosure, use, exhibition or other means</td> <td></td> <td></td> </tr> <tr> <td>"P" document published prior to the international filing date but later than the priority date claimed</td> <td></td> <td></td> </tr> </table>			* Special categories of cited documents:	"T"	Inter document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	"A" document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	"E" earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family	"O" document referring to an oral disclosure, use, exhibition or other means			"P" document published prior to the international filing date but later than the priority date claimed		
* Special categories of cited documents:	"T"	Inter document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention																		
"A" document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone																		
"E" earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art																		
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family																		
"O" document referring to an oral disclosure, use, exhibition or other means																				
"P" document published prior to the international filing date but later than the priority date claimed																				
Date of the actual completion of the international search 03 SEPTEMBER 1996		Date of mailing of the international search report <b>17 SEP 1996</b>																		
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230		Authorized officer RAY F. EBERT  Telephone No. (703) 308-0196																		

## INTERNATIONAL SEARCH REPORT

Int. national application No.  
PCT/US96/09511

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X — Y	BERD et al. Immunization with haptenized, autologous tumor cells induces inflammation of human melanoma metastases. Cancer Research. 15 May 1991, Vol. 51, pages 2731-2734, especially pages 2731-2732.	1-13 and 15-27 ———— 14 and 28-40
X — Y	BERD et al. Treatment of human melanoma with a hapten-modified autologous vaccine. Ann. New York Acad. Sci. 16 September 1993, Vol. 690, pages 147-152, see entire document.	1-13 and 15-27 ———— 14 and 28-40
Y	MACLEAN et al. Active immunization of human ovarian cancer patients against a common carcinoma (Thomsen-Friedenreich) determinant using a synthetic carbohydrate antigen. J. Immunotherapy. April 1992, Vol. 11, pages 292-305, see entire document.	1-41
Y	HELLSTROM et al. Tumor immunology: an overview. Ann. New York Acad. Sci. 16 September 1993, Vol. 690, pages 24-33, especially page 29, paragraph 5.	1-40
Y	WO 90/11764 A1 (FUNG ET AL) 18 October 1990 (18.10.90), Abstract and pages 1-3	41
Y	WO 87/06840 A1 (SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH) 19 November 1987 (19.11.87), see entire document, especially pages 1-4.	41
X — Y	BYSTRYN, J-C. Tumor vaccines. Cancer & Metastasis Reviews. January 1990, Vol. 9, pages 81-91, especially pages 82-83.	41 ———— 1-40
Y	HOOVER et al. Prospectively randomized trial of adjuvant active-specific immunotherapy for human colorectal cancer. Cancer. March 1985, Vol. 55, pages 1236-1243, see entire document.	41
Y	KANANGAT et al. Use of quantitative polymerase chain reaction to quantitate cytokine messenger RNA molecules. Molec. Immunol. 1992, Vol. 29, No. 10, pages 1229-1236, see entire document.	42-60
Y	NITTA et al. Expression of tumour necrosis factor- $\alpha$ , - $\beta$ and interferon- $\gamma$ genes within human neuroglial tumour cells and brain specimens. Cytokine. March 1994, pages 171-180, see entire document.	42-60

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US96/09511

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	KAASHOEK, J.G.J. Cytokine production by the bladder carcinoma cell line 5637: Rapid analysis of mRNA expression levels using a cDNA-PCR procedure. Lymphokine & Cytokine Res. 1991, Vol. 10, No. 3, pages 231-235, see entire document.	42-60
Y	PISA et al. Selective expression of interleukin 10, interferon $\gamma$ , and granulocyte-macrophage colony-stimulating factor in ovarian cancer biopsies. Proc. Natl. Acad. Sci. USA. August 1992, Vol. 89, pages 7708-7712, see entire document.	42-60
X — Y	LUSCHER et al. The pattern of cytokine gene expression in freshly excised human metastatic melanoma suggests a state of reversible anergy of tumor-infiltrating lymphocytes. Int. J. Cancer. October 1994, Vol. 57, pages 612-619, see entire document.	42-55 and 58 — 56-57, 59 and 60
Y	CARDING et al. A polymerase chain reaction assay for the detection of cytokine gene expression in small numbers of cells. J. Immunol. Meth. 22 July 1992, Vol. 151, pages 277-287, see entire document.	42-60
X — Y	GUNNING et al. Isolation and characterization of full-length cDNA clones for human $\alpha$ -, $\beta$ -, and $\gamma$ -actin mRNAs: skeletal but not cytoplasmic actins have an amino-terminal cysteine that is subsequently removed. Mol. Cell. Biol. May 1983, pages 787-795, see entire document.	49, 50, 52-54, 56 — 42-48 and 57-60
Y	WO 95/15334 A1 (CALIFORNIA PACIFIC MEDICAL CENTER RESEARCH INSTITUTE) 08 June 1995 (08.06.95), see entire document, especially cytokine sequences.	49, 52, 53, 56
Y	WO 94/21792 A2 (VIAGENE, INC.) 29 September 1994 (09.29.94) see entire document, especially cytokine sequences.	49, 50, 52-54, 56
Y	GB 2218420 A (BRITISH BIOTECHNOLOGY LIMITED) 15 November 1989 (11.15.89) see entire document, especially IL-4 sequence.	49, 50, 52-54, 56
X — Y	VIEIRA et al. Isolation and expression of human cytokine synthesis inhibitory factor cDNA clones: homology to Epstein-Barr virus open reading frame BCRF1. Proc. Natl. Acad. Sci. 15 February 1991, Vol. 88, pages 1172-1176, see entire document.	49, 50, 52-54, 56 — 42-48, 51, 55 and 57-60

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US96/09511

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐  
☐

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US96/09511

## A. CLASSIFICATION OF SUBJECT MATTER: IPC (6):

A61K 35/12, 38/00, 38/21, 39/00, 39/385, 45/00, 45/05, 47/00  
A01N 37/18; C12P 19/34; C12Q 1/68; G01N 33/531

## A. CLASSIFICATION OF SUBJECT MATTER: US CL :

424/85.2, 85.4, 184.1, 185.1, 193.1, 277.1, 278.1, 520; 435/6, 91.2, 961; 514/2

## B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

APS, WPIDS, BIOSIS, EMBASE

Search terms:

tumor/vaccine/melanoma/hapten/bcg/cyclophosphamide/interleukin/amplif?  
cytokine/expression/pcr/Berd,D

## BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

Group I. Claims 1-40, drawn to compositions and methods for treating cancer using hapten-modified tumor cell extracts.

Group II. Claim 41, drawn to a method of treating cancer using non-haptenized/irradiated tumor cell extracts mixed with adjuvant.

Group III. Claims 42-60, drawn to in vitro methods of screening for cytokine production by tumors using nucleic acid probes and amplification techniques.

The groups listed above do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: The special technical feature of Group I is hapten-modified tumor cell extracts claimed in a product and a method of treating; the special technical feature of Group II is non-haptenized/irradiated tumor cell extracts claimed in a method of treating; the special technical feature of Group III is a screening method based on the level of cytokine production, as determined by nucleic acid amplification and detection. The special technical features are not so linked as to form a single inventive concept because they differ in compositions (e.g., haptenized vs. non-haptenized cell extracts), method steps (e.g., methods of treatment vs. methods of screening), objectives (e.g., tumor cell killing vs. tumor cell monitoring), and outcomes (e.g., reduction or elimination of tumor vs. detection of tumor or response to treatment). Accordingly, the claims are not so linked by a special technical feature within the meaning of PCT Rule 13.2 so as to form a single inventive concept.

HPS Trailer Page  
for

# **Walk-Up\_Printing**

---

UserID: K

Printer: cm1\_9e12\_gblbptr

## **Summary**

<u>Document</u>	<u>Pages</u>	<u>Printed</u>	<u>Missed</u>	<u>Copies</u>
WO009640173	123	123	0	1
Total (1)	123	123	0	-



# K

Printed by HPS Server  
for

## Walk-Up\_Printing

---

Printer: cm1\_9e12\_gblbptr

Date: 09/24/03

Time: 11:48:02

### Document Listing

Document	Selected Pages	Page Range	Copies
WO009640173	123	1 - 123	1
Total (1)	123	-	-